ALFASIGMA S.p.A.

Italy

Back to Profile

1-100 of 510 for ALFASIGMA S.p.A. Sort by
Query
Aggregations
IP Type
        Trademark 357
        Patent 153
Jurisdiction
        World 168
        United States 167
        Europe 129
        Canada 46
Date
New (last 4 weeks) 2
2026 July 2
2026 June 2
2026 May 2
2026 April 2
See more
IPC Class
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca 32
A61K 31/541 - Non-condensed thiazines containing further heterocyclic rings 25
A61K 9/00 - Medicinal preparations characterised by special physical form 24
A61K 9/20 - Pills, lozenges or tablets 23
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline 22
See more
NICE Class
05 - Pharmaceutical, veterinary and sanitary products 344
10 - Medical apparatus and instruments 48
35 - Advertising and business services 42
01 - Chemical and biological materials for industrial, scientific and agricultural use 37
03 - Cosmetics and toiletries; cleaning, bleaching, polishing and abrasive preparations 25
See more
Status
Pending 30
Registered / In Force 480
  1     2     3     ...     6        Next Page

1.

Composition and Method to Correct Nutritional Deficiencies underlying Mood Disorder

      
Application Number 19417979
Status Pending
Filing Date 2025-12-12
First Publication Date 2026-07-16
Owner Alfasigma S.p.A. (Italy)
Inventor First, Eric R.

Abstract

Disclosed in certain embodiments are compositions and methods for treating, reducing or ameliorating symptoms of a mood disorder and/or re-establishment of homeostasis of nutritional deficiencies.

IPC Classes  ?

  • A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
  • A61K 31/05 - Phenols
  • A61K 31/121 - Ketones acyclic
  • A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
  • A61K 31/202 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having three or more double bonds, e.g. linolenic acid
  • A61K 31/385 - Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
  • A61K 31/593 - 9,10-Secocholestane derivatives, e.g. cholecalciferol, vitamin D3
  • A61K 33/06 - Aluminium, calcium or magnesiumCompounds thereof
  • A61K 33/30 - ZincCompounds thereof
  • A61K 36/30 - Boraginaceae (Borage family), e.g. comfrey, lungwort or forget-me-not
  • A61K 36/324 - Boswellia, e.g. frankincense
  • A61K 36/53 - Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
  • A61K 36/575 - Magnolia
  • A61K 36/756 - Phellodendron, e.g. corktree
  • A61K 36/81 - Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
  • A61K 36/84 - Valerianaceae (Valerian family), e.g. valerian
  • A61K 36/88 - Liliopsida (monocotyledons)

2.

ALLFerrium

      
Application Number 019395701
Status Pending
Filing Date 2026-07-15
Owner ALFASIGMA S.p.A. (Italy)
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

Prodotti farmaceutici, integratori alimentari e dietetici per uso umano.

3.

PREPARATION AND USES OF OBETICHOLIC ACID

      
Application Number 19353943
Status Pending
Filing Date 2025-10-09
First Publication Date 2026-06-18
Owner ALFASIGMA S.P.A (Italy)
Inventor
  • Steiner, André
  • Waenerlund Poulsen, Heidi
  • Jolibois, Emilie
  • Rewolinski, Melissa
  • Gross, Ralf
  • Sharp, Emma
  • Dubas-Fischer, Fiona
  • Eberlin, Alex

Abstract

The present invention relates to obeticholic acid: The present invention relates to obeticholic acid: The present invention relates to obeticholic acid: or a pharmaceutically acceptable salt, solvate or amino acid conjugate thereof. Obeticholic acid is useful for the treatment or prevention of a FXR mediated disease or condition, cardiovascular disease or cholestatic liver disease, and for reducing HDL cholesterol, for lowering triglycerides in a mammal, or for inhibition of fibrosis. The present invention also relates to processes for the synthesis of obeticholic acid.

IPC Classes  ?

  • C07J 9/00 - Normal steroids containing carbon, hydrogen, halogen, or oxygen, substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
  • A61K 9/20 - Pills, lozenges or tablets
  • A61K 31/575 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
  • C07J 51/00 - Normal steroids with unmodified cyclopenta[a]hydrophenanthrene skeleton not provided for in groups

4.

COMPOSITION FOR CORRECTION OF NUTRITIONAL DEFICIENCIES UNDERLYING MOOD DISORDER

      
Application Number IB2025000639
Publication Number 2026/125939
Status In Force
Filing Date 2025-12-12
Publication Date 2026-06-18
Owner ALFASIGMA S.P.A. (Italy)
Inventor First, Eric, R.

Abstract

Disclosed in- certain embodiments are compositions and methods for treating, reducing or ameliorating symptoms of a mood disorder and/or re-establishment of homeostasis of nutritional, deficiencies.

IPC Classes  ?

  • A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
  • A61K 36/185 - Magnoliopsida (dicotyledons)
  • A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
  • A61K 31/593 - 9,10-Secocholestane derivatives, e.g. cholecalciferol, vitamin D3
  • A61K 33/30 - ZincCompounds thereof
  • A61P 25/22 - Anxiolytics
  • A61P 25/24 - Antidepressants

5.

PHARMACEUTICAL COMPOSITIONS COMPRISING A JAK INHIBITOR

      
Application Number 19399876
Status Pending
Filing Date 2025-11-25
First Publication Date 2026-05-28
Owner Alfasigma S.p.A. (Italy)
Inventor
  • Alonzo, David
  • Li, Bei
  • Stefanidis, Dimitrios

Abstract

Pharmaceutical compositions comprising filgotinib maleate Form I and uses thereof are described herein.

IPC Classes  ?

  • A61K 31/541 - Non-condensed thiazines containing further heterocyclic rings
  • A61K 9/20 - Pills, lozenges or tablets
  • A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
  • A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]

6.

VELUSETRAG FOR USE IN THE TREATMENT OF CHRONIC INTESTINAL PSEUDO-OBSTRUCTION (CIPO)

      
Application Number 19105498
Status Pending
Filing Date 2023-09-20
First Publication Date 2026-05-07
Owner ALFASIGMA S.P.A. (Italy)
Inventor
  • Vesci, Loredana
  • Grimaldi, Maria
  • Giorgi, Fabrizio
  • Giovannini, Roberto
  • Barone, Michelangelo

Abstract

The invention relates to 1-isopropyl-2-oxo-1,2-dihydroquinoline-3-carboxylic acid {(1S,3R,5R)-8-[(R)-2-hydroxy-3-(methanesulfonyl-methyl-amino)propyl]-8-azabicyclo[3.2.1]oct-3-yl}amide (velusetrag) or a pharmaceutically acceptable salt thereof for use in a method of treating idiopathic chronic intestinal pseudo-obstruction (CIPO), neuropathic chronic intestinal pseudo-obstruction, or chronic intestinal pseudo-obstruction being secondary to neurodegeneration or to demyelinating conditions in a patient suffering from said diseases or conditions.

IPC Classes  ?

  • A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
  • A61K 9/00 - Medicinal preparations characterised by special physical form
  • A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
  • A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
  • A61P 25/02 - Drugs for disorders of the nervous system for peripheral neuropathies

7.

ALFERRIUM

      
Application Number 019353581
Status Pending
Filing Date 2026-04-24
Owner ALFASIGMA S.p.A. (Italy)
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

Pharmaceuticals, food and dietary supplements for humans.

8.

METHODS FOR THE TREATMENT OF PSORIATIC ARTHRITIS

      
Application Number 19206213
Status Pending
Filing Date 2025-05-13
First Publication Date 2026-04-23
Owner Alfasigma S.p.A. (Italy)
Inventor
  • Harrison, Pille
  • Meuleners, Luc
  • Tasset, Chantal Thérèse

Abstract

The present invention relates to compound according to Formula I: or a pharmaceutically acceptable salt thereof, or a solvate or the salt of a solvate thereof, pharmaceutical compositions comprising the same, and methods of treatment using the same, for use in the treatment of psoriatic arthritis, by administering the compound according to Formula I. The present invention relates to compound according to Formula I: or a pharmaceutically acceptable salt thereof, or a solvate or the salt of a solvate thereof, pharmaceutical compositions comprising the same, and methods of treatment using the same, for use in the treatment of psoriatic arthritis, by administering the compound according to Formula I.

IPC Classes  ?

  • A61K 31/541 - Non-condensed thiazines containing further heterocyclic rings
  • A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis

9.

BIOMARKERS FOR DETERMINING TREATMENT OF ULCERATIVE COLITIS WITH FILGOTINIB

      
Application Number EP2025072051
Publication Number 2026/027669
Status In Force
Filing Date 2025-07-31
Publication Date 2026-02-05
Owner ALFASIGMA S.P.A. (Italy)
Inventor Randall, Matthew

Abstract

Filgotinib or a pharmaceutically acceptable salt thereof for use in a method of treating ulcerative colitis is provided, along with methods of deciding whether to continue treating ulcerative colitis in a patient with filgotinib or a pharmaceutically acceptable salt. The treatments are based on the assessment of the levels of certain predictive biomarkers in the patient having ulcerative colitis.

IPC Classes  ?

  • A61K 31/541 - Non-condensed thiazines containing further heterocyclic rings
  • A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
  • G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

10.

BIOMARKERS FOR DETERMINING TREATMENT OF ULCERATIVE COLITIS WITH FILGOTINIB

      
Application Number EP2025072063
Publication Number 2026/027676
Status In Force
Filing Date 2025-07-31
Publication Date 2026-02-05
Owner ALFASIGMA S.P.A. (Italy)
Inventor
  • Malkov, Vladislav A.
  • Liang, Yan
  • Wendt, Emily
  • Levesque, Barrett

Abstract

Filgotinib or a pharmaceutically acceptable salt thereof for use in a method of treating ulcerative colitis is provided, along with methods of deciding whether to continue treating ulcerative colitis in a patient with filgotinib or a pharmaceutically acceptable salt. The treatments are based on the assessment of the levels of certain predictive biomarkers in the patient having ulcerative colitis.

IPC Classes  ?

  • G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

11.

VIVARA

      
Serial Number 99580396
Status Registered
Filing Date 2026-01-06
Registration Date 2026-07-14
Owner ALFASIGMA S.P.A. (Italy)
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

Vitamin A preparations; Vitamin supplements; Vitamin tablets

12.

VIVARA

      
Serial Number 99580399
Status Registered
Filing Date 2026-01-06
Registration Date 2026-07-14
Owner ALFASIGMA S.P.A. (Italy)
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

Vitamin A preparations; Vitamin supplements; Vitamin tablets

13.

VIVARA

      
Serial Number 99580405
Status Registered
Filing Date 2026-01-06
Registration Date 2026-07-14
Owner ALFASIGMA S.P.A. (Italy)
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

Vitamin A preparations; Vitamin supplements; Vitamin tablets

14.

DEPLIN PRO MOOD HEALTH

      
Serial Number 99558316
Status Registered
Filing Date 2025-12-19
Registration Date 2026-05-26
Owner ALFASIGMA S.P.A. (Italy)
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

Dietetic foods adapted for medical purposes consisting primarily of calcium salt of L-5 methyltetrahydrofolate

15.

DEPLINPRO MOOD HEALTH

      
Serial Number 99558324
Status Registered
Filing Date 2025-12-19
Registration Date 2026-05-26
Owner ALFASIGMA S.P.A. (Italy)
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

Dietetic foods adapted for medical purposes consisting primarily of calcium salt of L-5 methyltetrahydrofolate

16.

DEPLINPRO

      
Serial Number 99558327
Status Registered
Filing Date 2025-12-19
Registration Date 2026-05-26
Owner ALFASIGMA S.P.A. (Italy)
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

Dietetic foods adapted for medical purposes consisting primarily of calcium salt of L-5 methyltetrahydrofolate

17.

FARNESOID X RECEPTOR MODULATORS

      
Application Number 19198431
Status Pending
Filing Date 2025-05-05
First Publication Date 2025-12-11
Owner ALFASIGMA S.P.A (Italy)
Inventor
  • Pellicciari, Roberto
  • Gioiello, Antimo

Abstract

The present application provides a compound of formula I: The present application provides a compound of formula I: The present application provides a compound of formula I: or a pharmaceutically acceptable salt, solvate, or amino acid conjugate thereof, wherein R1-R10, m, n, p, and are as described herein. The present invention relates generally to F modulators and to methods of making and using said compounds.

IPC Classes  ?

  • C07J 43/00 - Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta[a]hydrophenanthrene skeleton
  • C07J 9/00 - Normal steroids containing carbon, hydrogen, halogen, or oxygen, substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
  • C07J 31/00 - Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
  • C07J 41/00 - Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
  • C07J 71/00 - Steroids in which the cyclopenta[a]hydrophenanthrene skeleton is condensed with a heterocyclic ring

18.

PHARMACEUTICAL COMPOSITIONS FOR COMBINATION THERAPY

      
Application Number 19233916
Status Pending
Filing Date 2025-06-10
First Publication Date 2025-12-04
Owner ALFASIGMA S.P.A (Italy)
Inventor
  • Pruzanski, Mark
  • Adorini, Luciano

Abstract

The present invention relates to a pharmaceutical composition comprising a combination of an FXR agonist and at least one lipid lowering agent (e.g., PPAR-alpha agonist, PPAR-delta agonist, PPAR-alpha and delta dual agonist, and/or statin). Also disclosed is use of the combination for the treatment or prevention of a FXR mediated disease or condition, such as primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC), portal hypertension, bile acid diarrhea, NAFLD (nonalcoholic fatty liver disease), NASH (non-alcohol-induced steatohepatitis), and other chronic liver diseases. The combination of the present invention is useful for the treatment or prevention of conditions related to elevated lipid and liver enzyme levels. The present invention also relates to packs or kits including the pharmaceutical combination.

IPC Classes  ?

  • A61K 31/575 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
  • A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
  • A61K 31/216 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
  • A61K 31/366 - Lactones having six-membered rings, e.g. delta-lactones
  • A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
  • A61K 31/451 - Non-condensed piperidines, e.g. piperocaine having a carbocyclic ring directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
  • A61K 31/56 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids
  • A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

19.

PHARMACEUTICAL COMPOSITIONS FOR COMBINATION THERAPY

      
Application Number 19233923
Status Pending
Filing Date 2025-06-10
First Publication Date 2025-12-04
Owner ALFASIGMA S.P.A (Italy)
Inventor
  • Pruzanski, Mark
  • Adorini, Luciano

Abstract

The present invention relates to a pharmaceutical composition comprising a combination of an FXR agonist and at least one lipid lowering agent (e.g., PPAR-alpha agonist, PPAR-delta agonist, PPAR-alpha and delta dual agonist, and/or statin). Also disclosed is use of the combination for the treatment or prevention of a FXR mediated disease or condition, such as primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC), portal hypertension, bile acid diarrhea, NAFLD (nonalcoholic fatty liver disease), NASH (non-alcohol-induced steatohepatitis), and other chronic liver diseases. The combination of the present invention is useful for the treatment or prevention of conditions related to elevated lipid and liver enzyme levels. The present invention also relates to packs or kits including the pharmaceutical combination.

IPC Classes  ?

  • A61K 31/575 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
  • A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
  • A61K 31/216 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
  • A61K 31/366 - Lactones having six-membered rings, e.g. delta-lactones
  • A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
  • A61K 31/451 - Non-condensed piperidines, e.g. piperocaine having a carbocyclic ring directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
  • A61K 31/56 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids
  • A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

20.

FERMENTATION PRODUCT FOR THE TREATMENT OF INFLAMMATORY DISEASES

      
Application Number 18875012
Status Pending
Filing Date 2023-06-30
First Publication Date 2025-11-27
Owner ALFASIGMA S.P.A. (Italy)
Inventor
  • Vesci, Loredana
  • Giorgi, Fabrizio

Abstract

The present invention relates to a fermentation product obtained by a fermentation process of at least one bacterial strain in the presence of at least one vegetable extract. The fermentation product of a bacterial may comprise alimentary and/or pharmaceutically acceptable components or comprised in medical food or nutritional composition. The fermentation product and is useful for the treatment and/or prevention of inflammatory diseases, in particular, inflammatory bowel disease.

IPC Classes  ?

  • A61K 36/48 - Fabaceae or Leguminosae (Pea or Legume family)CaesalpiniaceaeMimosaceaePapilionaceae
  • A61K 35/747 - Lactobacilli, e.g. L. acidophilus or L. brevis
  • A61K 36/31 - Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
  • A61K 36/324 - Boswellia, e.g. frankincense
  • A61K 36/539 - Scutellaria (skullcap)
  • A61K 36/82 - Theaceae (Tea family), e.g. camellia
  • A61K 36/9066 - Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
  • A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
  • A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]

21.

DICLOREUM JOINT PLUS

      
Application Number 019279949
Status Registered
Filing Date 2025-11-21
Registration Date 2026-03-06
Owner ALFASIGMA S.p.A. (Italy)
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

Food supplements; Pharmaceuticals; Pomades for medical purposes; Topical gels for medical and therapeutic use; Anti-inflammatory gels; Body gels for pharmaceutical use; Anti-inflammatories; Anti-inflammatory ointments; Anti-inflammatory sprays; Anti-inflammatory preparations; Anti-inflammatory analgesic plasters; Homeopathic anti-inflammatory ointments; Non-steroidal anti-inflammatory drugs.

22.

LACTICASEIBACILLUS PARACASEI DG(R) CNCM I-1572 DSM 34154 FOR USE IN A METHOD OF TREATING DYSBIOSIS IN PATIENTS WITH IBS

      
Application Number 18865784
Status Pending
Filing Date 2023-05-17
First Publication Date 2025-10-23
Owner ALFASIGMA S.P.A. (Italy)
Inventor
  • Biffi, Andrea
  • Guglielmetti, Simone Domenico
  • Fiore, Walter

Abstract

The object of the present invention is to use the strain of bacteria named Lacticaseibacillus paracasei DG® CNCM I-1572 DSM 34154 for use in a method of treating dysbiosis, particularly in patients with IBS (Irritable Bowel Syndrome), preferably without constipation, who have high fecal levels of Collinsella aerofaciens.

IPC Classes  ?

  • A61K 35/747 - Lactobacilli, e.g. L. acidophilus or L. brevis
  • A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system

23.

METANXPRO

      
Serial Number 99432731
Status Registered
Filing Date 2025-10-08
Registration Date 2026-07-14
Owner ALFASIGMA S.P.A. (Italy)
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

Folic acid/B-complex medical food supplement

24.

METANX PRO NERVE HEALTH

      
Serial Number 99432936
Status Registered
Filing Date 2025-10-08
Registration Date 2026-07-14
Owner ALFASIGMA S.P.A. (Italy)
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

Folic acid/B-complex medical food supplement

25.

METANXPRO NERVE HEALTH

      
Serial Number 99432734
Status Registered
Filing Date 2025-10-08
Registration Date 2026-07-14
Owner ALFASIGMA S.P.A. (Italy)
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

Folic acid/B-complex medical food supplement

26.

SALTS AND PHARMACUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS

      
Application Number 19033986
Status Pending
Filing Date 2025-01-22
First Publication Date 2025-09-18
Owner Alfasigma S.p.A. (Italy)
Inventor
  • Sabourault, Nicolas Luc
  • De Faveri, Carla
  • Sheikh, Ahmad
  • Wigernick, Piel

Abstract

The present invention discloses salts of a Compound 1: The present invention discloses salts of a Compound 1: The present invention discloses salts of a Compound 1: useful in the prophylaxis and/or treatment of inflammatory conditions, autoimmune diseases, proliferative diseases, allergy, transplant rejection, diseases involving degradation and/or disruption of cartilage homeostasis, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6 or interferons.

IPC Classes  ?

  • C07D 471/04 - Ortho-condensed systems
  • A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
  • A61K 31/541 - Non-condensed thiazines containing further heterocyclic rings
  • A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
  • H04L 9/40 - Network security protocols
  • H04L 67/104 - Peer-to-peer [P2P] networks
  • H04L 67/51 - Discovery or management thereof, e.g. service location protocol [SLP] or web services
  • H04W 4/80 - Services using short range communication, e.g. near-field communication [NFC], radio-frequency identification [RFID] or low energy communication
  • H04W 8/24 - Transfer of terminal data
  • H04W 92/18 - Interfaces between hierarchically similar devices between terminal devices

27.

USES OF FARNESOID X RECEPTOR AGONISTS

      
Application Number 18858674
Status Pending
Filing Date 2023-04-21
First Publication Date 2025-09-18
Owner ALFASIGMA S.P.A (Italy)
Inventor Capozza, Thomas

Abstract

The present invention relates to FXR agonist compounds and methods of use thereof for treating, ameliorating, or promoting recovery from diseases and disorders, such as acute diseases of the liver, for example, severe alcohol-associated hepatitis.

IPC Classes  ?

  • A61K 31/575 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
  • A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
  • A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

28.

CEREFOLIN BRAIN WELLNESS

      
Serial Number 99213901
Status Registered
Filing Date 2025-06-02
Registration Date 2025-10-21
Owner ALFASIGMA S.P.A. (Italy)
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

FOLATE/B-COMPLEX IN A MEDICAL FOOD SUPPLEMENT

29.

Miscellaneous Design

      
Serial Number 99199136
Status Registered
Filing Date 2025-05-23
Registration Date 2026-01-27
Owner ALFASIGMA S.P.A. (Italy)
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

medical food supplements featuring folate being a b-complex

30.

COMBINATION THERAPY

      
Application Number 18833630
Status Pending
Filing Date 2023-01-30
First Publication Date 2025-05-22
Owner ALFASIGMA S.P.A (Italy)
Inventor
  • Civitarese, Antonio
  • Vernillet, Laurent

Abstract

The present disclosure relates to a combination of an FXR agonist and a fibrate. Also disclosed is use of the combination for the treatment, amelioration or prevention of an FXR mediated disease or condition, such as primary biliary cholangitis (PBC).

IPC Classes  ?

  • A61K 31/575 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
  • A61K 31/195 - Carboxylic acids, e.g. valproic acid having an amino group
  • A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

31.

Miscellaneous Design

      
Application Number 019186977
Status Registered
Filing Date 2025-05-14
Registration Date 2025-09-04
Owner ALFASIGMA S.p.A. (Italy)
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

Pharmaceutical preparations; Pharmaceutical products for treating respiratory diseases; Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Anti-viral agents; Antifungal medication; Pharmaceutical preparations for treating rheumatological diseases; Pharmaceutical preparations for the prevention of inflammatory diseases; Pharmaceutical preparations for the treatment of inflammatory diseases; Antiviral drugs for treating HIV; Pharmaceutical preparations for treating arthritis.

32.

Jyseleca

      
Application Number 019186974
Status Registered
Filing Date 2025-05-14
Registration Date 2025-09-04
Owner ALFASIGMA S.p.A. (Italy)
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

Pharmaceutical preparations; Pharmaceutical products for treating respiratory diseases; Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Anti-viral agents; Antifungal medication; Pharmaceutical preparations for treating rheumatological diseases; Pharmaceutical preparations for the prevention of inflammatory diseases; Pharmaceutical preparations for the treatment of inflammatory diseases; Antiviral drugs for treating HIV; Pharmaceutical preparations for treating arthritis.

33.

ENTEROLACTIS

      
Serial Number 99020631
Status Registered
Filing Date 2025-01-28
Registration Date 2026-05-26
Owner ALFASIGMA S.P.A. (Italy)
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

Dietary supplements; Pharmaceutical products and preparations including live milk enzymes and probiotic enzymes for medical and pharmaceutical use, namely, lactic ferment containing Lactobacillus paracasei CNCM I-1572; dietary supplement beverage for restoring gut microbiota balance, reducing diarrhea incidence and duration and improving symptoms in irritable bowel syndrome (IBS) for medical use; dietary supplemental drinks in the nature of vitamin beverages; dietary fiber to rebalance intestinal bacterial flora, strengthening the immune system, and assisting digestion; biological nutritional supplements for medical use; probiotic bacteria preparations for medical use

34.

LP-DG

      
Serial Number 99020636
Status Registered
Filing Date 2025-01-28
Registration Date 2025-12-30
Owner ALFASIGMA S.P.A. (Italy)
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

Dietary supplements; Dietary fiber to rebalance intestinal bacterial flora, strengthening the immune system, and assisting digestion; Nutritional supplements; Pharmaceutical preparations, in particular, milk enzymes and probiotic enzymes for use in improving symptoms in irritable bowel syndrome (IBS); Dietary supplemental drinks in the nature of vitamin and mineral beverages, dietary supplemental drinks for medical use

35.

ORODISPERSIBLE COMPOSITIONS COMPRISING BETAMETHASONE PHOSPHATE

      
Application Number EP2024069613
Publication Number 2025/012363
Status In Force
Filing Date 2024-07-11
Publication Date 2025-01-16
Owner ALFASIGMA S.P.A. (Italy)
Inventor
  • Marzi, Mauro
  • Giorgi, Fabrizio
  • Pace, Silvia
  • Meloni, Pietro

Abstract

The present invention relates to a pharmaceutical composition in the form of orodispersible tablets comprising betamethasone phosphate together with pharmaceutically acceptable excipients. A process for obtaining the composition comprising betamethasone phosphate and its use in the treatment and/or prevention of diseases in which betamethasone phosphate is useful is also described.

IPC Classes  ?

  • A61K 9/00 - Medicinal preparations characterised by special physical form
  • A61K 9/16 - AgglomeratesGranulatesMicrobeadlets
  • A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
  • A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
  • A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
  • A61K 47/36 - PolysaccharidesDerivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
  • A61K 9/20 - Pills, lozenges or tablets

36.

FLUOROMETHYL-CARNITINE FOR USE AS A CHOLINE TRIMETHYLAMINE (TMA) LYASE INHIBITOR

      
Application Number EP2024067429
Publication Number 2024/261237
Status In Force
Filing Date 2024-06-21
Publication Date 2024-12-26
Owner ALFASIGMA S.P.A. (Italy)
Inventor
  • Giannini, Giuseppe
  • Battistuzzi, Gianfranco
  • Taddei, Maurizio
  • Cini, Elena

Abstract

The present invention relates to a compound of formula (I) for use in the treatment of disorders and/or conditions associated with high trimethylamine (TMA) and/or trimethylamine N-oxide (TMAO) plasma levels, or for use in the treatment of disorders and/or conditions associated with a high ratio of TMA/TMAO plasma concentrations as well as relative composition and method of preparation.

IPC Classes  ?

  • A61K 31/205 - Amine addition salts of organic acidsInner quaternary ammonium salts, e.g. betaine, carnitine
  • A61K 9/00 - Medicinal preparations characterised by special physical form
  • A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
  • A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
  • A61P 3/00 - Drugs for disorders of the metabolism
  • A61P 9/00 - Drugs for disorders of the cardiovascular system
  • A61P 41/00 - Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
  • A61P 43/00 - Drugs for specific purposes, not provided for in groups
  • C07C 229/22 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated the carbon skeleton being further substituted by oxygen atoms

37.

FARNESOID X RECEPTOR MODULATORS

      
Application Number 18800808
Status Pending
Filing Date 2024-08-12
First Publication Date 2024-12-05
Owner ALFASIGMA S.P.A (Italy)
Inventor Pellicciari, Roberto

Abstract

The present invention provides a compound of formula (I): or a pharmaceutically acceptable salt, solvate, or amino acid conjugate thereof, wherein R1, R2, R3, R4, R5, and R6 are as described herein. The present invention relates generally to selective FXR agonists and to methods of making and using them. The present invention provides a compound of formula (I): or a pharmaceutically acceptable salt, solvate, or amino acid conjugate thereof, wherein R1, R2, R3, R4, R5, and R6 are as described herein. The present invention relates generally to selective FXR agonists and to methods of making and using them.

IPC Classes  ?

  • A61K 31/575 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
  • A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
  • A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
  • C07J 9/00 - Normal steroids containing carbon, hydrogen, halogen, or oxygen, substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
  • C07J 31/00 - Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
  • C07J 41/00 - Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
  • C07J 71/00 - Steroids in which the cyclopenta[a]hydrophenanthrene skeleton is condensed with a heterocyclic ring

38.

USE OF LACTOBACILLUS PARACASEI BACTERIAL STRAINS IN THE TREATMENT OF NEWBORNS

      
Application Number 18579158
Status Pending
Filing Date 2022-07-15
First Publication Date 2024-10-24
Owner Alfasigma S.p.A. (Italy)
Inventor
  • Biffi, Andrea
  • Fiore, Walter

Abstract

The present invention relates to at least one strain of bacteria belonging to the species Lactobacillus paracasei, preferably Lactobacillus paracasei DG® CNCM I-1572 and/or Lactobacillus paracasei LPC-01 DSM 26760, and compositions thereof for use in newborns and/or from 1 month to ≤12 months subjects in the treatment, preventive and/or curative, of gastro-intestinal tract disorders of an inflammatory and/or functional nature, gastro-intestinal infections by pathogenic micro-organisms, gastro-intestinal infections by parasites, allergies, immune-mediated or autoimmune disorders, and in the support of the subject's growth.

IPC Classes  ?

  • A61K 35/747 - Lactobacilli, e.g. L. acidophilus or L. brevis
  • A61K 35/745 - Bifidobacteria
  • A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
  • A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system

39.

NUTRACEUTICAL COMPOSITIONS FOR THE TREATMENT OR PREVENTION OF TRIMETHYLAMINURIA

      
Application Number EP2024059508
Publication Number 2024/209109
Status In Force
Filing Date 2024-04-08
Publication Date 2024-10-10
Owner ALFASIGMA S.P.A. (Italy)
Inventor
  • Giannini, Giuseppe
  • Barone, Michelangelo

Abstract

Lactobacillus paracaseiAllium sativumCassia angustifoliaCassia angustifolia, and compositions containing it, for use in treatment and/or prevention of trimethylaminuria (TMAU).

IPC Classes  ?

  • A23L 33/00 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof
  • A61K 31/593 - 9,10-Secocholestane derivatives, e.g. cholecalciferol, vitamin D3
  • A61K 31/714 - Cobalamins, e.g. cyanocobalamin, vitamin B12
  • A61K 33/04 - Sulfur, selenium or telluriumCompounds thereof
  • A61K 33/30 - ZincCompounds thereof
  • A61K 35/747 - Lactobacilli, e.g. L. acidophilus or L. brevis
  • A61K 36/482 - Cassia, e.g. golden shower tree
  • A61K 36/8962 - Allium, e.g. garden onion, leek, garlic or chives
  • A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

40.

Compound useful for the treatment of degenerative and inflammatory diseases

      
Application Number 18741974
Grant Number 12558360
Status In Force
Filing Date 2024-06-13
First Publication Date 2024-10-03
Grant Date 2026-02-24
Owner ALFASIGMA S.P.A. (Italy)
Inventor
  • Menet, Christel Jeanne Marie
  • Smits, Koen Kurt

Abstract

A novel compound able to inhibit JAK is disclosed, that comprises a compound of Formula 1: The compound may be prepared as a pharmaceutical composition, and may be used for the treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, inflammatory conditions, autoimmune diseases, proliferative diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6.

IPC Classes  ?

  • A61K 31/541 - Non-condensed thiazines containing further heterocyclic rings
  • A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
  • A61P 11/06 - Antiasthmatics
  • C07D 471/04 - Ortho-condensed systems

41.

Pharmaceutical compositions comprising a JAK inhibitor

      
Application Number 18628560
Grant Number 12502394
Status In Force
Filing Date 2024-04-05
First Publication Date 2024-08-22
Grant Date 2025-12-23
Owner Alfasigma S.p.A. (Italy)
Inventor
  • Alonzo, David
  • Li, Bei
  • Stefanidis, Dimitrios

Abstract

FIG. 1 and uses thereof are described herein.

IPC Classes  ?

  • A61K 31/541 - Non-condensed thiazines containing further heterocyclic rings
  • A61K 9/20 - Pills, lozenges or tablets
  • A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
  • A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]

42.

FERMENTATION PRODUCT FOR USE IN THE TREATMENT OF DISEASES ASSOCIATED WITH METABOLIC SYNDROME AND HEPATIC STEATOSIS

      
Application Number EP2024052559
Publication Number 2024/160988
Status In Force
Filing Date 2024-02-01
Publication Date 2024-08-08
Owner ALFASIGMA S.P.A. (Italy)
Inventor
  • Vesci, Loredana
  • Giannini, Giuseppe
  • Giorgi, Fabrizio

Abstract

The present inven on relates to a bacterial strain, Lac plan bacillus plantarum DSM 33683, and to a composi on comprising the fermenta on product of this bacterial strain, obtained in the presence of at least one plant extract. The composi on is useful in the treatment and/or preven on of diseases associated with metabolic syndrome or in the treatment and/or preven on of insulin resistance syndrome and in the treatment and/or preven on of hepa c steatosis. It also relates to the process for obtaining the fermenta on product and the composi on comprising the same.

IPC Classes  ?

  • A23L 33/00 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof
  • A61K 9/00 - Medicinal preparations characterised by special physical form
  • A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
  • A61K 35/747 - Lactobacilli, e.g. L. acidophilus or L. brevis
  • A61K 36/185 - Magnoliopsida (dicotyledons)
  • A61K 36/31 - Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
  • A61K 36/38 - Clusiaceae, Hypericaceae or Guttiferae (Hypericum or Mangosteen family), e.g. common St. Johnswort
  • A61K 36/482 - Cassia, e.g. golden shower tree
  • A61K 36/74 - Rubiaceae (Madder family)
  • A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
  • A61P 3/04 - AnorexiantsAntiobesity agents
  • A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
  • A61P 5/00 - Drugs for disorders of the endocrine system
  • A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

43.

ESOXX

      
Serial Number 98673476
Status Registered
Filing Date 2024-07-30
Registration Date 2025-05-20
Owner Alfasigma S.p.A. (Italy)
NICE Classes  ?
  • 05 - Pharmaceutical, veterinary and sanitary products
  • 10 - Medical apparatus and instruments

Goods & Services

Pharmaceutical preparations for the protection of the esophagus in case of gastroesophageal reflux; Medicines for the treatment of gastrointestinal diseases; Gastrointestinal treatment preparations; Gastroenteric treatment preparations; Pharmaceutical preparations for the treatment of esophagitis; Pharmaceutical cough treatment preparations; Pharmaceutical preparations for treating asthma Medical devices for use in treating gastroesophageal reflux

44.

VESVEIN

      
Application Number 019059823
Status Registered
Filing Date 2024-07-26
Registration Date 2024-11-08
Owner ALFASIGMA S.p.A. (Italy)
NICE Classes  ?
  • 03 - Cosmetics and toiletries; cleaning, bleaching, polishing and abrasive preparations
  • 05 - Pharmaceutical, veterinary and sanitary products
  • 10 - Medical apparatus and instruments

Goods & Services

Pomades for cosmetic purposes; Salves [non-medicated]. Pharmaceuticals; Pomades for medical purposes; Medicinal ointments; Medicated ointments for application to the skin; Food supplements; Dietary and nutritional supplements; Pharmaceutical drugs; Cardiovascular drugs for use in treating hypertension; Cardiovascular drugs used in treating arrhythmias; Cardiovascular drugs used in angina pectoris; Cardiovascular drugs used in myocardial infarction; Medicines for the treatment of cardiovascular and cerebrovascular diseases; Cardiovascular drugs used in treating congestive heart failure (CHF); Cardiovascular drugs used in treating shocks; Cardiovascular agents for medical purposes; Cardiovascular preparations; Pharmaceutical preparations for the treatment of cardiovascular disease; Cardiovascular pharmaceuticals; Medicated mouth care preparations; Blood tonics. Apparatus for drug administration; Drug-coated stents for thrombosis; Cardiovascular instruments; Apparatus for the diagnosis of cardiovascular diseases; Cardiovascular catheters; Heart monitors; Apparatus for blood monitoring [for medical use]; Pharmaceutical instruments.

45.

VESVEIN

      
Application Number 019059839
Status Registered
Filing Date 2024-07-26
Registration Date 2024-11-08
Owner ALFASIGMA S.p.A. (Italy)
NICE Classes  ?
  • 03 - Cosmetics and toiletries; cleaning, bleaching, polishing and abrasive preparations
  • 05 - Pharmaceutical, veterinary and sanitary products
  • 10 - Medical apparatus and instruments

Goods & Services

Pomades for cosmetic purposes; Salves [non-medicated]. Pharmaceuticals; Pomades for medical purposes; Medicinal ointments; Medicated ointments for application to the skin; Food supplements; Dietary and nutritional supplements; Pharmaceutical drugs; Cardiovascular drugs for use in treating hypertension; Cardiovascular drugs used in treating arrhythmias; Cardiovascular drugs used in angina pectoris; Cardiovascular drugs used in myocardial infarction; Medicines for the treatment of cardiovascular and cerebrovascular diseases; Cardiovascular drugs used in treating congestive heart failure (CHF); Cardiovascular drugs used in treating shocks; Cardiovascular agents for medical purposes; Cardiovascular preparations; Pharmaceutical preparations for the treatment of cardiovascular disease; Cardiovascular pharmaceuticals; Medicated mouth care preparations; Blood tonics. Apparatus for drug administration; Drug-coated stents for thrombosis; Cardiovascular instruments; Apparatus for the diagnosis of cardiovascular diseases; Cardiovascular catheters; Heart monitors; Apparatus for blood monitoring [for medical use]; Pharmaceutical instruments.

46.

Miscellaneous Design

      
Application Number 019034104
Status Registered
Filing Date 2024-05-29
Registration Date 2024-09-10
Owner ALFASIGMA S.p.A. (Italy)
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

Pharmaceutical preparations for the treatment of cardiovascular disease.

47.

VELUSETRAG FOR USE IN THE TREATMENT OF CHRONIC INTESTINAL PSEUDO-OBSTRUCTION (CIPO)

      
Document Number 03263063
Status Pending
Filing Date 2023-09-20
Open to Public Date 2024-03-28
Owner ALFASIGMA S.P.A. (Italy)
Inventor
  • Vesci, Loredana
  • Grimaldi, Maria
  • Giorgi, Fabrizio
  • Giovannini, Roberto
  • Barone, Michelangelo

IPC Classes  ?

  • A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings

48.

VELUSETRAG FOR USE IN THE TREATMENT OF CHRONIC INTESTINAL PSEUDO-OBSTRUCTION (CIPO)

      
Application Number EP2023075925
Publication Number 2024/061960
Status In Force
Filing Date 2023-09-20
Publication Date 2024-03-28
Owner ALFASIGMA S.P.A. (Italy)
Inventor
  • Vesci, Loredana
  • Grimaldi, Maria
  • Giorgi, Fabrizio
  • Giovannini, Roberto
  • Barone, Michelangelo

Abstract

The invention relates to 1-isopropyl-2-oxo-1,2-dihydroquinoline-3-carboxylic acid {(1S,3R,5R)-8-[(R)-2-hydroxy-3-(methanesulfonyl-methyl-amino)propyl]-8- azabicyclo[3.2.1]oct-3-yl}amide (velusetrag) or a pharmaceutically acceptable salt thereof for use in a method of treating idiopathic chronic intestinal pseudo-obstruction (CIPO), neuropathic chronic intestinal pseudo-obstruction, or chronic intestinal pseudo-obstruction being secondary to neurodegeneration or to demyelinating conditions in a patient suffering from said diseases or conditions.

IPC Classes  ?

  • A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
  • A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system

49.

USE OF A COMPOSITION COMPRISING MICROORGANISMS TO INCREASE THE INTESTINAL PRODUCTION OF BUTYRIC ACID, FOLIC ACID OR NIACIN AND/OR DECREASE THE INTESTINAL PRODUCTION OF SUCCINIC ACID

      
Application Number 18493221
Status Pending
Filing Date 2023-10-24
First Publication Date 2024-02-15
Owner ALFASIGMA S.P.A. (Italy)
Inventor
  • Guglielmetti, Simone Domenico
  • Rossi, Ruggero
  • Fiore, Walter
  • Biffi, Andrea

Abstract

Use of a composition comprising bacteria to increase the intestinal production of butyric acid, folic acid or niacin and/or to decrease the intestinal production of succinic acid. Use of a composition comprising bacteria to increase the intestinal production of butyric acid, folic acid or niacin and/or to decrease the intestinal production of succinic acid. Moreover, the present invention relates to the use of said composition for the treatment and/or prevention of an intestinal butyrate- and/or succinate-dependent pathological condition. In particular, for the treatment and/or the prevention of intestinal inflammation, diarrhoea, ulcerative colitis or intestinal colopathies.

IPC Classes  ?

  • A61K 35/747 - Lactobacilli, e.g. L. acidophilus or L. brevis
  • A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics
  • A23L 33/21 - Addition of substantially indigestible substances, e.g. dietary fibres
  • A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
  • A61K 9/00 - Medicinal preparations characterised by special physical form
  • A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate

50.

FERMENTATION PRODUCT FOR THE TREATMENT OF INFLAMMATORY DISEASES

      
Application Number EP2023068130
Publication Number 2024/008597
Status In Force
Filing Date 2023-06-30
Publication Date 2024-01-11
Owner ALFASIGMA S.P.A. (Italy)
Inventor
  • Vesci, Loredana
  • Giorgi, Fabrizio

Abstract

The present invention relates to a fermentation product obtained by a fermentation process of at least one bacterial strain in the presence of at least one vegetable extract. The fermentation product of a bacterial may comprise alimentary and/or pharmaceutically acceptable components or comprised in medical food or nutritional composition. The fermentation product and is useful for the treatment and/or prevention of inflammatory diseases, in particular, inflammatory bowel disease.

IPC Classes  ?

  • A61K 35/742 - Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
  • A61K 36/31 - Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
  • A61K 36/324 - Boswellia, e.g. frankincense
  • A61K 36/45 - Ericaceae or Vacciniaceae (Heath or Blueberry family), e.g. blueberry, cranberry or bilberry
  • A61K 36/48 - Fabaceae or Leguminosae (Pea or Legume family)CaesalpiniaceaeMimosaceaePapilionaceae
  • A61K 36/539 - Scutellaria (skullcap)
  • A61K 36/906 - Zingiberaceae (Ginger family)
  • A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
  • A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
  • C12R 1/24 - Lactobacillus brevis

51.

Salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders

      
Application Number 18306867
Grant Number 12234235
Status In Force
Filing Date 2023-04-25
First Publication Date 2023-12-21
Grant Date 2025-02-25
Owner ALFASIGMA S.P.A. (Italy)
Inventor
  • Sabourault, Nicolas Luc
  • De Faveri, Carla
  • Sheikh, Ahmad
  • Wigerinck, Piet

Abstract

The present invention discloses salts of a Compound 1: useful in the prophylaxis and/or treatment of inflammatory conditions, autoimmune diseases, proliferative diseases, allergy, transplant rejection, diseases involving degradation and/or disruption of cartilage homeostasis, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6 or interferons.

IPC Classes  ?

  • C07D 471/04 - Ortho-condensed systems
  • A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
  • A61K 31/541 - Non-condensed thiazines containing further heterocyclic rings
  • A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
  • H04L 9/40 - Network security protocols
  • H04L 67/104 - Peer-to-peer [P2P] networks
  • H04L 67/51 - Discovery or management thereof, e.g. service location protocol [SLP] or web services
  • H04W 4/80 - Services using short range communication, e.g. near-field communication [NFC], radio-frequency identification [RFID] or low energy communication
  • H04W 8/24 - Transfer of terminal data
  • H04W 92/18 - Interfaces between hierarchically similar devices between terminal devices

52.

Nutrælth

      
Application Number 018959053
Status Registered
Filing Date 2023-12-04
Registration Date 2024-03-27
Owner ALFASIGMA S.p.A. (Italy)
NICE Classes  ?
  • 41 - Education, entertainment, sporting and cultural services
  • 42 - Scientific, technological and industrial services, research and design
  • 44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services

Goods & Services

Education services relating to pharmacy; Publication of the results of clinical trials for pharmaceutical preparations; Adult education services relating to pharmacy; Providing of training in the field of health care and nutrition; Provision of educational services relating to health; Education services relating to health; Provision of educational courses in the field of diet and health care; Training in the field of medicine; Organization of seminars and conventions in the field of medicine. Consultancy pertaining to pharmacology; Consultancy relating to pharmaceutical research and development; Consultancy in the field of pharmaceutical research; Development of pharmaceutical preparations and medicines; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Research and development in the pharmaceutical and biotechnology fields; Research on the subject of pharmaceuticals. Pharmaceutical advice; Pharmaceutical services; Medication counseling; Advisory services relating to pharmaceuticals; Provision of pharmaceutical information; Pharmacy advice; Medical services; Professional consultancy relating to health; Public health counseling; Health advice and information services; Individual medical counseling services provided to patients; Human healthcare services; Information services relating to health care; Consulting services relating to health care.

53.

LACTICASEIBACILLUS PARACASEI DG® CNCM I‐1572 DSM 34154 FOR USE IN A METHOD OF TREATING DYSBIOSIS IN PATIENTS WITH IBS

      
Document Number 03247954
Status Pending
Filing Date 2023-05-17
Open to Public Date 2023-11-23
Owner ALFASIGMA S.P.A. (Italy)
Inventor
  • Biffi, Andrea
  • Guglielmetti, Simone Domenico
  • Fiore, Walter

Abstract

The object of the present invention is to use the strain of bacteria named Lacticaseibacillus paracasei DG® CNCM I1572 DSM 34154 for use in a method of treating dysbiosis, particularly in patients with IBS (Irritable Bowel Syndrome), preferably without constipation, who have high fecal levels of Collinsella aerofaciens.

IPC Classes  ?

  • A61K 35/00 - Medicinal preparations containing materials or reaction products thereof with undetermined constitution
  • A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system

54.

LACTICASEIBACILLUS PARACASEI DG® CNCM I‐1572 DSM 34154 FOR USE IN A METHOD OF TREATING DYSBIOSIS IN PATIENTS WITH IBS

      
Application Number IB2023055083
Publication Number 2023/223237
Status In Force
Filing Date 2023-05-17
Publication Date 2023-11-23
Owner ALFASIGMA S.P.A. (Italy)
Inventor
  • Biffi, Andrea
  • Guglielmetti, Simone Domenico
  • Fiore, Walter

Abstract

Lacticaseibacillus paracaseiCollinsella aerofaciensCollinsella aerofaciens.

IPC Classes  ?

  • A61K 35/00 - Medicinal preparations containing materials or reaction products thereof with undetermined constitution
  • A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system

55.

Bacterial strains, the compositions thereof and use thereof in a method for the treatment of vitamin D deficiency, and disorders associated therewith

      
Application Number 17798882
Grant Number 12472214
Status In Force
Filing Date 2021-04-28
First Publication Date 2023-06-22
Grant Date 2025-11-18
Owner ALFASIGMA S.P.A (Italy)
Inventor
  • Biffi, Andrea
  • Fiore, Walter

Abstract

The present invention relates to bacterial strains for use in the treatment of vitamin D deficiency and/or insufficiency and/or diseases, symptoms and/or disorders associated thereto. Furthermore, the present invention relates to compositions comprising at least one of said bacterial strains and at least one vitamin D, preferably vitamin D3, and to the use thereof in the treatment of said vitamin D deficiency and/or insufficiency and/or diseases, symptoms or disorders associated thereto.

IPC Classes  ?

  • A61K 35/747 - Lactobacilli, e.g. L. acidophilus or L. brevis
  • A61K 31/593 - 9,10-Secocholestane derivatives, e.g. cholecalciferol, vitamin D3
  • A61P 3/02 - Nutrients, e.g. vitamins, minerals

56.

COMPOSITION COMPRISING METHYLFOLATE

      
Application Number 17998534
Status Pending
Filing Date 2021-05-10
First Publication Date 2023-06-15
Owner ALFASIGMA S.P.A. (Italy)
Inventor
  • Marzi, Mauro
  • Santaniello, Mose'
  • Meloni, Pietro
  • Paris, Marta
  • Giorgi, Fabrizio
  • Merlo Pich, Emilio

Abstract

The present invention describes a pharmaceutical and/or nutritional composition comprising methylfolate in the form of granules, together with a carnitine derivative salt, pharmaceutically acceptable excipients, and optionally other pharmaceutical or nutraceutical active ingredients. The composition is useful for oral administration. The invention also relates to the process for obtaining the composition comprising methylfolate in the form of granules and the use thereof for the treatment of disorders associated with a reduction of methylfolate, wherein methylfolate is useful.

IPC Classes  ?

  • A61K 9/20 - Pills, lozenges or tablets
  • A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
  • A61K 9/16 - AgglomeratesGranulatesMicrobeadlets
  • A61P 25/24 - Antidepressants
  • A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
  • A61K 31/205 - Amine addition salts of organic acidsInner quaternary ammonium salts, e.g. betaine, carnitine
  • A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
  • A61K 31/714 - Cobalamins, e.g. cyanocobalamin, vitamin B12
  • A61K 9/28 - DrageesCoated pills or tablets

57.

ONLIGOL

      
Application Number 1732317
Status Registered
Filing Date 2023-03-24
Registration Date 2023-03-24
Owner ALFASIGMA S.P.A. (Italy)
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

Laxatives; laxatives for detoxification purposes; medicines for intestinal disorders; pharmaceutical preparations for treating gastrointestinal disorders.

58.

FERMENTED SUPERNATANT AND POSTBIOTIC COMPOSITIONS USEFUL IN THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES.

      
Application Number EP2022078187
Publication Number 2023/061978
Status In Force
Filing Date 2022-10-11
Publication Date 2023-04-20
Owner ALFASIGMA S.P.A. (Italy)
Inventor
  • Giannini, Giuseppe
  • Vesci, Loredana
  • Milazzo, Ferdinando Maria
  • Merlo Pich, Emilio

Abstract

The present invention relates to a supernatant obtained by the fermentation of a bacterial strain selected from the group of: Akkermansia muciniphila, Lactobacillus rhamnosus, Bifidobacterium breve Reuter and Lactobacillus paracasei in the presence of at least one plant extract selected from the group of: Allium sativum, Salvia miltiorrhiza, Zingiber officinale, Myrciaria dubia, Garcinia cambogia, Garcinia mangosteen, Cassia angustifolia leaves and Nelumbo nucifera leaves. It is also described the process for obtaining such supernatant, the composition comprising thereof and its use in the treatment and/or prevention of diseases associated with cardiovascular diseases.

IPC Classes  ?

  • A61K 31/00 - Medicinal preparations containing organic active ingredients
  • A61K 35/741 - Probiotics
  • A61K 35/745 - Bifidobacteria
  • A61K 35/747 - Lactobacilli, e.g. L. acidophilus or L. brevis
  • A61K 36/00 - Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
  • A61P 9/00 - Drugs for disorders of the cardiovascular system

59.

LOVOLDYL

      
Application Number 018862955
Status Registered
Filing Date 2023-04-17
Registration Date 2023-08-18
Owner ALFASIGMA S.p.A. (Italy)
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

Laxatives; Laxatives for detoxification purposes; Medicines for intestinal disorders; Pharmaceutical preparations for treating gastrointestinal disorders.

60.

Process for mesalazine solid formulations

      
Application Number 18047964
Grant Number 12201729
Status In Force
Filing Date 2022-10-19
First Publication Date 2023-04-06
Grant Date 2025-01-21
Owner ALFASIGMA S.P.A. (Italy)
Inventor Labruzzo, Carla

Abstract

The present invention relates to a process to prepare solid pharmaceutical forms comprising a quantity of mesalazine comprised between 75 and 95%, i.e. between 1000 and 1600 mg of drug per dosage unit. Furthermore, the present invention relates to a granulate and/or tablets obtained/obtainable with the process according to the invention, preferably coated to allow the con-trolled release of the drug. Finally, the present invention relates to the use of the granulate and/or the tablets as a medicament, preferably for the treatment of chronic inflammatory pathologies that preferably affect the intestinal tract.

IPC Classes  ?

  • A61K 9/16 - AgglomeratesGranulatesMicrobeadlets
  • A61K 9/20 - Pills, lozenges or tablets
  • A61K 9/28 - DrageesCoated pills or tablets
  • A61K 31/606 - Salicylic acidDerivatives thereof having amino groups

61.

ONLIGOL

      
Serial Number 79370776
Status Registered
Filing Date 2023-03-24
Registration Date 2024-04-09
Owner ALFASIGMA S.P.A. (Italy)
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

Laxatives; laxatives for detoxification purposes; medicines for intestinal disorders; pharmaceutical preparations for treating gastrointestinal disorders

62.

ONLIGOL

      
Application Number 018851419
Status Registered
Filing Date 2023-03-21
Registration Date 2023-07-01
Owner ALFASIGMA S.p.A. (Italy)
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

Laxatives; Laxatives for detoxification purposes; Medicines for intestinal disorders; Pharmaceutical preparations for treating gastrointestinal disorders.

63.

CLIN 4000

      
Application Number 018851520
Status Registered
Filing Date 2023-03-21
Registration Date 2023-07-01
Owner ALFASIGMA S.p.A. (Italy)
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

Laxatives; Laxatives for detoxification purposes; Medicines for intestinal disorders; Pharmaceutical preparations for treating gastrointestinal disorders.

64.

USE OF LACTOBACILLUS PARACASEI BACTERIAL STRAINS IN THE TREATMENT OF NEWBORNS

      
Document Number 03222905
Status Pending
Filing Date 2022-07-15
Open to Public Date 2023-01-19
Owner ALFASIGMA S.P.A. (Italy)
Inventor
  • Biffi, Andrea
  • Fiore, Walter

Abstract

The present invention relates to at least one strain of bacteria belonging to the species Lactobacillus paracasei, preferably Lactobacillus paracasei DG® CNCM I-1572 and/or Lactobacillus paracasei LPC-01 DSM 26760, and compositions thereof for use in newborns and/or from 1 month to ?12 months subjects in the treatment, preventive and/or curative, of gastro-intestinal tract disorders of an inflammatory and/or functional nature, gastro-intestinal infections by pathogenic micro-organisms, gastro-intestinal infections by parasites, allergies, immune-mediated or autoimmune disorders, and in the support of the subject's growth.

IPC Classes  ?

  • A61K 35/745 - Bifidobacteria
  • A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

65.

COMPOSITIONS COMPRISING BACTERIAL STRAINS FOR USE IN INCREASNG THE BIOAVAILABILITY OF AMINO ACIDS DERIVED FROM PROTEINS

      
Application Number 17774432
Status Pending
Filing Date 2020-11-05
First Publication Date 2022-12-29
Owner ALFASIGMA S.P.A. (Italy)
Inventor
  • Biffi, Andrea
  • Fiore, Walter

Abstract

Compositions are described and related methods and food products for increasing the blood bioavailability of amino acids derived from proteins, preferably proteins of plant origin, based on a mixture M including at least one bacterial strain, preferably Lactobacillus paracasei DG® CNCM I-1572 and/or Lactobacillus paracasei LPC-S01™ DSM 26760. Furthermore, the mixture M is described, as well as the compositions and related methods and food products based on mixture M and further comprises at least one protein, preferably proteins of plant origin, or a peptide or an amino acid.

IPC Classes  ?

  • A61K 35/744 - Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
  • A23L 33/185 - Vegetable proteins
  • A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics
  • A23L 33/17 - Amino acids, peptides or proteins
  • A61K 35/745 - Bifidobacteria
  • A61K 35/747 - Lactobacilli, e.g. L. acidophilus or L. brevis
  • A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
  • A61P 3/00 - Drugs for disorders of the metabolism

66.

COMPOSITIONS BASED ON BACTERIAL STRAINS AND BERRY EXTRACTS AND THEIR USE AS ANTI-INFLAMMATORIES

      
Application Number 17761920
Status Pending
Filing Date 2020-09-21
First Publication Date 2022-11-24
Owner ALFASIGMA S.P.A. (Italy)
Inventor
  • Biffi, Andrea
  • Fiore, Walter

Abstract

A composition comprising a mixture comprising or, alternatively, consisting of: at least one bacterial strain selected from a group comprising or, alternatively, consisting of bacterial strains belonging to the species Lactobacillus paracasei, Lactobacillus rhamnosus, Bifidobacterium bifidum and Bifidobacterium animalis subsp. Lactis, and preferably, at least one extract of at least one species of berries comprising a polyphenol fraction of said berries and a related method wherein said composition is used as an immunomodulatory and anti-inflammatory agent are disclosed.

IPC Classes  ?

  • A61K 35/745 - Bifidobacteria
  • A61K 35/747 - Lactobacilli, e.g. L. acidophilus or L. brevis
  • A61K 36/45 - Ericaceae or Vacciniaceae (Heath or Blueberry family), e.g. blueberry, cranberry or bilberry
  • A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]

67.

TOPSTER

      
Application Number 1694644
Status Registered
Filing Date 2022-08-01
Registration Date 2022-08-01
Owner ALFASIGMA S.P.A. (Italy)
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

Pharmaceuticals.

68.

COMPOSITIONS BASED ON BACTERIAL STRAINS AND THEIR USE AS ANTI-INFLAMMATORIES

      
Application Number 17762017
Status Pending
Filing Date 2020-09-21
First Publication Date 2022-11-10
Owner ALFASIGMA S.P.A. (Italy)
Inventor
  • Biffi, Andrea
  • Fiore, Walter

Abstract

A composition comprising a mixture comprising or, alternatively, consisting of: at least one bacterial strain selected from a group comprising or, alternatively, consisting of bacterial strains belonging to the species Lactobacillus paracasei, Lactobacillus rhamnosus, Bifidobacterium bifidum and Bifidobacterium animalis subsp. Lactis, and preferably, at least one extract of at least one species of berries comprising a polyphenol fraction of said berries. and a related method wherein the composition is an immunomodulatory and anti-inflammatory agent are described.

IPC Classes  ?

  • A61K 35/747 - Lactobacilli, e.g. L. acidophilus or L. brevis
  • A61K 35/745 - Bifidobacteria
  • A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
  • A61K 36/45 - Ericaceae or Vacciniaceae (Heath or Blueberry family), e.g. blueberry, cranberry or bilberry

69.

Bacterial strains, their compositions and their use for the treatment of gastrointestinal disorders

      
Application Number 17761980
Grant Number 12447183
Status In Force
Filing Date 2020-09-21
First Publication Date 2022-10-27
Grant Date 2025-10-21
Owner ALFASIGMA S.P.A. (Italy)
Inventor
  • Biffi, Andrea
  • Fiore, Walter

Abstract

L. paracasei LPC-S01™ (DSM 26760) and related method for the treatment of gastrointestinal diseases, disorders or symptoms, in particular functional gastrointestinal disorders, such as, for example irritable bowel syndrome (IBS) are described.

IPC Classes  ?

  • A61K 35/745 - Bifidobacteria
  • A61K 35/747 - Lactobacilli, e.g. L. acidophilus or L. brevis
  • A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system

70.

BACTERIAL STRAINS, THEIR COMPOSITIONS AND THEIR USE FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS

      
Application Number 17761843
Status Pending
Filing Date 2020-09-21
First Publication Date 2022-10-13
Owner ALFASIGMA S.P.A. (Italy)
Inventor
  • Biffi, Andrea
  • Fiore, Walter

Abstract

Bacterial strains including B. breve BbIBS01 (DSM 33231), B. breve BbIBS02 (DSM 33232), B. animalis subsp. lactis BIIBS01 (DSM 33233) and L. plantarum LpIBS01 (DSM 33234) are described. Furthermore, compositions are further described comprising a mixture of at least one or more of the aforementioned bacterial strains and, optionally, at least one further bacterial strain, selected from a bacterial strain L. casei DG® (CNCM I-1572) and bacterial strain L. paracasei LPC-S01™ (DSM 26760) and related method for the treatment of gastrointestinal diseases, disorders or symptoms, in particular functional gastrointestinal disorders, such as, irritable bowel syndrome (IBS).

IPC Classes  ?

  • C12N 1/20 - BacteriaCulture media therefor
  • A61K 35/745 - Bifidobacteria
  • A61K 35/747 - Lactobacilli, e.g. L. acidophilus or L. brevis
  • A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system

71.

BIFIDOBACTERIUM BIFIDUM BACTERIAL STRAIN, THE COMPOSITIONS THEREOF AND RELATED USES

      
Application Number 17620648
Status Pending
Filing Date 2020-07-08
First Publication Date 2022-10-06
Owner ALFASIGMA S.P.A. (Italy)
Inventor
  • Guglielmetti, Simone Domenico
  • Taverniti, Valentina
  • Biffi, Andrea
  • Fiore, Walter

Abstract

The present invention relates to a bacterial strain of Bifidobacterium bifidum MIMBb23 sg (=BbfIBSCM) DSM 32708, compositions comprising said bacterial strain and the use thereof in methods for the treatment of gastrointestinal disorders, in particular functional gastrointestinal disorders, such as, for example, irritable bowel syndrome (IBS) or inflammatory bowel diseases (IBDs).

IPC Classes  ?

  • A61K 35/745 - Bifidobacteria
  • A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
  • A61K 9/00 - Medicinal preparations characterised by special physical form

72.

Pharmaceutical compositions for combination therapy

      
Application Number 17700317
Grant Number 12337003
Status In Force
Filing Date 2022-03-21
First Publication Date 2022-09-08
Grant Date 2025-06-24
Owner ALFASIGMA S.P.A (Italy)
Inventor
  • Pruzanski, Mark
  • Adorini, Luciano

Abstract

The present invention relates to a pharmaceutical composition comprising a combination of an FXR agonist and at least one lipid lowering agent (e.g., PPAR-alpha agonist, PPAR-delta agonist, PPAR-alpha and delta dual agonist, and/or statin). Also disclosed is use of the combination for the treatment or prevention of a FXR mediated disease or condition, such as primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC), portal hypertension, bile acid diarrhea, NAFLD (nonalcoholic fatty liver disease), NASH (non-alcohol-induced steatohepatitis), and other chronic liver diseases. The combination of the present invention is useful for the treatment or prevention of conditions related to elevated lipid and liver enzyme levels. The present invention also relates to packs or kits including the pharmaceutical combination.

IPC Classes  ?

  • A61K 31/575 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
  • A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
  • A61K 31/216 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
  • A61K 31/366 - Lactones having six-membered rings, e.g. delta-lactones
  • A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
  • A61K 31/451 - Non-condensed piperidines, e.g. piperocaine having a carbocyclic ring directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
  • A61K 31/56 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids
  • A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

73.

PHARMACEUTICAL COMPOSITIONS IN THE FORM OF GEL CONTAINING XYLOGLUCAN AND ALCOHOLS FOR THE CONTROLLED RELEASE OF ACTIVE INGREDIENTS

      
Application Number 17596509
Status Pending
Filing Date 2020-06-11
First Publication Date 2022-08-04
Owner ALFASIGMA S.P.A. (Italy)
Inventor
  • Viscomi, Giuseppe Claudio
  • Maffei, Paola
  • Bruno, Cristiana
  • Federici, Mascia
  • Dispenza, Clelia
  • Sabatino, Maria Antonietta

Abstract

The invention relates to gel compositions comprising pharmaceutical active ingredients. The composition comprises xyloglucan at a concentration between 0.1% and 10.0% by total weight of the composition, together with a primary alcohol at a concentration between 20.0 and 50.0% by total weight of the composition. The invention also describes a process for the preparation of the composition and its use in the treatment of pathologies wherein a controlled release of the active principle is useful.

IPC Classes  ?

  • A61K 9/06 - OintmentsBases therefor
  • A61K 47/36 - PolysaccharidesDerivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
  • A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
  • A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

74.

BUCCAL MUCOADHESIVE GEL CONTAINING PROBIOTICS FOR USE IN THE PREVENTION AND TREATMENT OF PERIODONTAL DISEASES.

      
Application Number EP2022051430
Publication Number 2022/161893
Status In Force
Filing Date 2022-01-24
Publication Date 2022-08-04
Owner ALFASIGMA S.P.A. (Italy)
Inventor
  • Giannini, Giuseppe
  • Merlo Pich, Emilio
  • Ragusa, Irene
  • Nardone, Giulia Nerina
  • Valenti, Piera

Abstract

The present invention relates to mucoadhesive gels comprising probiotics, to the process for their preparation and to their use for the prevention and treatment of pathologies of the 5 oral cavity.

IPC Classes  ?

  • A61K 9/00 - Medicinal preparations characterised by special physical form
  • A61K 9/06 - OintmentsBases therefor
  • A61K 35/745 - Bifidobacteria
  • A61K 35/747 - Lactobacilli, e.g. L. acidophilus or L. brevis
  • A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
  • A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
  • A61K 47/38 - CelluloseDerivatives thereof
  • A61P 1/02 - Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis

75.

PHARMACEUTICAL COMPOSITIONS COMPRISING A FXR AGONIST AND A FIBRATE FOR USE IN THE TREATMENT OF CHOLESTATIC LIVER DISEASE

      
Application Number 17615186
Status Pending
Filing Date 2020-05-29
First Publication Date 2022-07-21
Owner ALFASIGMA S.P.A (Italy)
Inventor
  • Macconell, Leigh A.
  • Pencek, Richard

Abstract

The present invention relates to a pharmaceutical composition comprising a combination of an FXR agonist and a fibrate. Also disclosed is use of the combination for the treatment, amelioration or prevention of an FXR mediated disease or condition, such as primary biliary cholangitis (PBC).

IPC Classes  ?

  • A61K 31/575 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
  • A61K 31/195 - Carboxylic acids, e.g. valproic acid having an amino group
  • A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

76.

METHODS AND INTERMEDIATES FOR THE PREPARATION OF BILE ACID DERIVATIVES

      
Application Number 17342057
Status Pending
Filing Date 2021-06-08
First Publication Date 2022-04-28
Owner ALFASIGMA S.P.A (Italy)
Inventor
  • Pellicciari, Roberto
  • Gioiello, Antimo
  • Galvin, Gabriel
  • Lewis, Ii, Ronald D.
  • Yanik, Mathew
  • Kim, Myoung Goo
  • Leusink, Frederik Ronald
  • Koning, Bartjan
  • Hensel, Thomas

Abstract

The present disclosure relates to methods and novel intermediates useful in the preparation of a compound of formula I The present disclosure relates to methods and novel intermediates useful in the preparation of a compound of formula I The present disclosure relates to methods and novel intermediates useful in the preparation of a compound of formula I or pharmaceutically acceptable salt, hydrate, solvate or amino acid, sulfate or glucuronide conjugate, or prodrug thereof.

IPC Classes  ?

  • C07J 9/00 - Normal steroids containing carbon, hydrogen, halogen, or oxygen, substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
  • C07J 31/00 - Normal steroids containing one or more sulfur atoms not belonging to a hetero ring

77.

NOVEL DNA SEQUENCES ENCODING HUMAN SCFVs ANTIBODIES WITH NEUTRALIZING ACTIVITY AGAINST SARS-CORONAVIRUS-2 AND USES THEREOF

      
Application Number EP2021064161
Publication Number 2022/053188
Status In Force
Filing Date 2021-05-27
Publication Date 2022-03-17
Owner ALFASIGMA S.P.A. (Italy)
Inventor
  • De Santis, Rita
  • Minenkova, Olga
  • Merlo Pich, Emilio

Abstract

The present invention relates to a human single chain variable antigen-binding antibody fragment (scFv) that specifically binds to the receptor binding domain (RBD) of the spike protein of SARS-CoV-2 virus and variants of the virus having one or more mutations in the spike protein, and has a neutralizing activity against SARS-CoV-2 and its spike protein variants, wherein said antibody fragment comprises at least one of the sequences selected from an amino acid sequence having any of SEQ ID NOs:2, 4, 6, 8, 10 or 12 or a sequence being at least 85% identical, preferably at least 90% identical, more preferably at least 95% identical, still more preferably at least 98% identical to any of said sequences, wherein the VH CDR3 sequence is ARDLSVAGAFDI (SEQ ID NO:44), wherein the VH and the VL variable regions are connected by a linker, and wherein the antibody fragment binds at least to the following residues within the human ACE2 receptor binding motif of the RBD of the spike protein of the SARS-CoV-2 virus L455, F456,Y473, N487 and Y489 and to a DNA sequence encoding said fragments, pharmaceutical compositions comprising said antibody fragments and derivatives thereof as well as said antibody fragments and the pharmaceutical compositions comprising them for use in a method of preventing or treating a SARS-CoV-2-virus-mediated disorder, preferably COVID-19.

IPC Classes  ?

  • A61P 31/14 - Antivirals for RNA viruses
  • C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
  • A61K 39/00 - Medicinal preparations containing antigens or antibodies

78.

Compound useful for the treatment of degenerative and inflammatory diseases

      
Application Number 17230483
Grant Number 12042498
Status In Force
Filing Date 2021-04-14
First Publication Date 2021-12-02
Grant Date 2024-07-23
Owner ALFASIGMA S.P.A. (Italy)
Inventor
  • Menet, Christel Jeanne Marie
  • Smits, Koen Kurt

Abstract

A novel compound able to inhibit JAK is disclosed, that comprises a compound of Formula I: The compound may be prepared as a pharmaceutical composition, and may be used for the treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, inflammatory conditions, autoimmune diseases, proliferative diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6.

IPC Classes  ?

  • A61K 31/541 - Non-condensed thiazines containing further heterocyclic rings
  • A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
  • C07D 471/04 - Ortho-condensed systems

79.

Pharmaceutical compositions comprising a JAK inhibitor

      
Application Number 17186446
Grant Number 11975008
Status In Force
Filing Date 2021-02-26
First Publication Date 2021-11-18
Grant Date 2024-05-07
Owner ALFASIGMA S.P.A. (Italy)
Inventor
  • Alonzo, David
  • Li, Bei
  • Stefanidis, Dimitrios

Abstract

FIG. 1 and uses thereof are described herein.

IPC Classes  ?

  • A61K 31/541 - Non-condensed thiazines containing further heterocyclic rings
  • A61K 9/20 - Pills, lozenges or tablets
  • A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
  • A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]

80.

COMPOSITION COMPRISING METHYLFOLATE

      
Application Number EP2021062374
Publication Number 2021/228788
Status In Force
Filing Date 2021-05-10
Publication Date 2021-11-18
Owner ALFASIGMA S.P.A. (Italy)
Inventor
  • Marzi, Mauro
  • Santaniello, Mosè
  • Meloni, Pietro
  • Paris, Marta
  • Giorgi, Fabrizio
  • Merlo Pich, Emilio

Abstract

The present invention describes a pharmaceutical and/or nutritional composition comprising methylfolate in the form of granules, together with a carnitine derivative salt, pharmaceutically acceptable excipients, and optionally other pharmaceutical or nutraceutical active ingredients. The composition is useful for oral administration. The invention also relates to the process for obtaining the composition comprising methylfolate in the form of granules and the use thereof for the treatment of disorders associated with a reduction of methylfolate, wherein methylfolate is useful.

IPC Classes  ?

  • A61K 9/16 - AgglomeratesGranulatesMicrobeadlets
  • A61K 9/20 - Pills, lozenges or tablets
  • A61K 9/28 - DrageesCoated pills or tablets
  • A61K 31/00 - Medicinal preparations containing organic active ingredients
  • A61P 25/00 - Drugs for disorders of the nervous system

81.

DG

      
Application Number 1622482
Status Registered
Filing Date 2021-05-31
Registration Date 2021-05-31
Owner ALFASIGMA S.P.A. (Italy)
NICE Classes  ?
  • 01 - Chemical and biological materials for industrial, scientific and agricultural use
  • 03 - Cosmetics and toiletries; cleaning, bleaching, polishing and abrasive preparations
  • 05 - Pharmaceutical, veterinary and sanitary products
  • 35 - Advertising and business services

Goods & Services

Raw materials [chemical], chemicals, additives and chemical compounds intended for industry for formulation and preparation of pharmaceutical, parapharmaceutical, nutraceutical, nutritional, food and dietary substances, food and dietary substances for medical use, dietary food and substances for babies for medical use, functional and nutraceutical food for medical use, food supplements for medical use, food supplements for humans, pharmaceutical products and food supplements, in accordance with EU regulation 2017/745; bacteriological preparations other than those for medical and veterinary use; bacteriological cultures to be added to foods, milk and dairy products, including fermented milk products, other than for medical and veterinary use; cultures of microorganisms not for medical purposes; cultures of microorganisms for use in the manufacture of food and beverages; preparations based on microorganisms, not for medical or veterinary use; bacterial substances for industrial use; bacteria used in food production; chemical preparations for use in the manufacture of cosmetics; bacterial preparations for the food industry; additive bacterial cultures for food products; bacterial preparations and cultures not for medical use; lactic ferments and bacterial preparations used for production of foods; antioxidants, fatty acids, proteins, enzymes, liposomes, cultures of microorganisms, bacteria to produce lactic acid and probiotic compounds all intended for the production of pharmaceuticals, dietary compounds for human use, baby food, food supplements, nutritional supplements, dietary supplements, food supplements for medical use and dietary foods; probiotic bacteria for the food industry; preparations of probiotic bacteria [not for medical use]; fermentation extracts for industrial use. Cosmetic products containing live or dead microorganisms; cosmetics and cosmetic preparations based on microorganisms, lactic bacteria and / or bifidobacterial; functional cosmetics based on microorganisms, lactic bacteria and / or bifidobacterial; non-medicated cosmetics; cosmetics containing hyaluronic acid and microorganisms. Preparations of microorganisms for medical or veterinary use; bacteriological preparations for medical and veterinary use; pharmaceutical products and preparations, including pharmaceutical products, parapharmaceuticals, lactic ferments, probiotic ferments, probiotics, nutraceuticals, nutritional; pharmaceutical products and food supplements, in accordance with EU regulation 2017/745; bacteriological cultures to add to milk, dairy products and fermented milk for medical purposes; lactic bacteria for medical purposes; food additives based on milk and dairy products, including fermented milk products, for use as a dietary supplement (not for medical purposes); vitamins; dietary fibers to aid digestion; dietary fibers for use as an ingredient in the manufacture of dietary supplements, vitamin drinks, dietary drinks for medical use; food and dietetic substances for medical use, food and dietetic substances for infants for medical use, functional foods and nutraceuticals for medical use, food supplements for medical use and food supplements for humans comprising at least one selected compound trace elements, mineral salts, oxides of metals, metal hydroxides, phosphoric acid salts, vitamins, proteins, milk proteins, microelements, organic acids and their salts, inorganic acids and their salts, saturated or unsaturated fatty acids, oils, fats and lipids of vegetable origin and / or animal, amino acids, glucose, starch, rice starch, carbohydrates, saccharic esters of fatty acids, sunflower lecithin and lecithin, omega-3 and omega-6; probiotic bacterial preparations for medical and animal use. Wholesale and retail services for the benefit of third parties including by mail order and through the means of communication including the internet, in relation to raw materials [chemical], chemicals, additives and chemical compounds intended for industry for formulation and preparation of pharmaceutical, parapharmaceutical, nutraceutical, nutritional, food and dietary substances, food and dietary substances for medical use, dietary food and substances for babies for medical use, functional and nutraceutical food for medical use, food supplements for medical use, food supplements for humans, medical preparations, namely medical devices pursuant to EU regulation 2017/745, pharmaceutical products and food supplements, in accordance with EU regulation 2017/745, bacteriological preparations other than those for medical and veterinary use, bacteriological cultures to be added to foods, milk and dairy products, including fermented milk products, other than for medical and veterinary use, cultures of microorganisms not for medical purposes, cultures of microorganisms for use in the manufacture of food and beverages, preparations based on microorganisms, not for medical or veterinary use, bacterial substances for industrial use, bacteria used in food production, chemical preparations for cosmetics, bacterial preparations for the food industry, additive bacterial cultures for food products, bacterial preparations and cultures not for medical use, lactic ferments and bacterial preparations used for production of foods, antioxidants, fatty acids, proteins, enzymes, liposomes, cultures of microorganisms, bacteria to produce lactic acid and probiotic compounds all intended for the production of pharmaceuticals, dietary compounds for human use, baby food, food supplements, nutritional supplements, dietary supplements, food supplements for medical use and dietary foods, probiotic bacteria for the food industry, preparations of probiotic bacteria [not for medical use], fermentation extracts for industrial use, probiotic bacterial preparations for medical and animal use; wholesale and retail services for the benefit of third parties including by mail order and through the means of communication including the internet, in relation to cosmetic products containing live or dead microorganisms, cosmetics and cosmetic preparations based on microorganisms, lactic bacteria and / or bifidobacterial, functional cosmetics based on microorganisms, lactic bacteria and / or bifidobacterial, non-medicated cosmetics, cosmetics containing hyaluronic acid and microorganisms; wholesale and retail services for the benefit of third parties including by mail order and through the means of communication including the internet, in relation to preparations of microorganisms for medical or veterinary use, bacteriological preparations for medical and veterinary use, pharmaceutical products and preparations, including pharmaceutical products, parapharmaceuticals, lactic ferments, probiotic ferments, probiotics, nutraceuticals, nutritional, medical preparations, namely medical devices pursuant to EU regulation 2017/745, pharmaceutical products and food supplements, in accordance with EU regulation 2017/745, bacteriological cultures to add to milk, dairy products and fermented milk for medical purposes, lactic bacteria for medical purposes, food additives based on milk and dairy products, including fermented milk products, for use as a dietary supplement (not for medical purposes), vitamins, dietary fibers to aid digestion, dietary fibers for use as an ingredient in the manufacture of dietary supplements, vitamin drinks, dietary drinks for medical use, food and dietetic substances for medical use, food and dietetic substances for infants for medical use, functional foods and nutraceuticals for medical use, food supplements for medical use and food supplements for humans comprising at least one selected compound trace elements, mineral salts, oxides of metals, metal hydroxides, phosphoric acid salts, vitamins, proteins, milk proteins, microelements, organic acids and their salts, inorganic acids and their salts, saturated or unsaturated fatty acids, oils, fats and lipids of vegetable origin and / or animal, amino acids, glucose, starch, rice starch, carbohydrates, saccharic esters of fatty acids, sunflower lecithin and lecithin, omega-3 and omega-6.

82.

Can we simplify the journey in UC?

      
Application Number 1622244
Status Registered
Filing Date 2021-09-17
Registration Date 2021-09-17
Owner ALFASIGMA S.P.A. (Italy)
NICE Classes  ?
  • 35 - Advertising and business services
  • 36 - Financial, insurance and real estate services
  • 44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services

Goods & Services

Promoting public awareness of treatment guidelines; promoting public awareness of inflammatory and autoimmune diseases; administratively assisting patients in enrolling in pharmaceutical reimbursement and benefit programs. Financially assisting patients, pharmacists, and healthcare providers with respect to reimbursement of medicines. Information and advisory services relating to pharmaceuticals, diseases and medical conditions and treatment, including such services provided on-line from a computer network or the Internet; providing information and advisory services regarding the diagnosis and treatment of diseases and medical disorders.

83.

DG

      
Application Number 018571139
Status Registered
Filing Date 2021-10-04
Registration Date 2022-02-18
Owner ALFASIGMA S.p.A. (Italy)
NICE Classes  ?
  • 01 - Chemical and biological materials for industrial, scientific and agricultural use
  • 05 - Pharmaceutical, veterinary and sanitary products
  • 35 - Advertising and business services

Goods & Services

Raw materials [chemical], chemicals, chemical additives and compositions for use in industry for the formulation and preparation of the following goods: Pharmaceuticals, Parapharmaceutical preparations, nutraceutical preparations, Nutritional products, Dietetic food and substances, dietetic food and substances adapted for medical use, Dietetic food and substances for babies, adapted for medical use, Functional foodstuffs and nutraceuticals for medical purposes, Food-supplements for medical use, Dietary supplements for human beings; Bacteriological preparations, other than for medical and veterinary use; Bacteriological cultures for adding to food, milk and dairy products, including fermented milk products, other than for medical and veterinary use; Cultures of microorganisms other than for medical use; Cultures of microorganisms for use in making food and beverages; Preparations of microorganisms, other than for medical and veterinary use; Bacterial substances for industrial use; Bacteria for use in food manufacture; Chemical preparations for use in the manufacture of cosmetics; Bacterial preparations for the food industry; Bacterial cultures for addition to food products; Bacterial preparations and cultures other than for medical use; Milk ferments and bacterial preparations for use in producing foodstuffs; Antioxidants, fatty acids, proteins, enzymes, liposomes, cultures of microorganisms, bacteria for producing lactic acid and probiotic compositions, all for use in producing the following goods: Pharmaceuticals, Dietetic compounds for humans, Food for babies, Food supplements, Nutritional supplements, Dietetic supplements, Food-supplements for medical use and Dietetic food; Probiotic bacteria for the food industry; Preparations of probiotic bacteria, other than for medical; Fermentation extracts for industrial purposes. Pharmaceuticals; Medical and veterinary preparations containing live and/or dead microorganisms; Sanitary preparations for medical purposes; Preparations of microorganisms for medical or veterinary use; Bacteriological preparations for medical and veterinary purposes; Pharmaceuticals and pharmaceutical preparations, including the following goods: Pharmaceuticals, Parapharmaceutical preparations, Milk ferments, Probiotic ferments, Probiotics, Nutraceuticals, Nutritional preparations; Medical preparations for food, nutritional, dietetic, vitamin, nutraceutical, probiotic, prebiotic and pharmaceutical use; Pharmaceutical preparations and dietary supplements; Bacteriological cultures for adding to milk, dairy products and fermented milk, for medical use; Lactic bacteria, For medical purposes; Food additives based on milk and dairy products, including fermented milk products, for use as dietary supplement (not for medical use); Vitamins; Dietary fiber to aid digestion; Dietary fibre for use as ingredients in the production of dietary supplements, vitamin drinks, dietetic beverages adapted for medical use; Dietetic food and substances adapted for medical use, dietetic food and substances for babies for medical use, functional and nutraceutical food, not for medical use, dietary supplements for medical use and dietary supplements for human beings featuring at least one of the following compounds: Trace elements, Mineral salts, Metal oxides, Metal hydroxides, Salts of phosphoric acid, Vitamins, Protein, Antioxidants, Enzymes, Liposomes, Hyaluronic acid, Milk proteins, Microelements, Organic acids and their salts, Inorganic acids and their salts, Saturated and unsaturated fatty acids, Oils, fats and lipids of plant and/or animal origin, Amino acid, Glucose, Stiffeners, Rice starch, Carbohydrates, Saccharic esters in fatty acids, Lecithin and sunflower lecithin, Omega 3 and Omega-6; Probiotic bacterial formulations for medical use, Probiotic bacterial preparations for animals. Wholesaling and retailing for others including via mail order and via communications media including the internet, in relation the following goods: Raw materials [chemical], chemicals, chemical additives and compounds for use in industry for the formulation and preparation in relation the following goods: pharmaceuticals, Parapharmaceuticals, Nutraceuticals, nutritional, dietetic food and substances, Dietetic foodstuffs and substances adapted for medical use, Dietetic food and substances for babies adapted for medical use, Functional foodstuffs and nutraceuticals for medical purposes, Nutritional additives for medical purposes, Dietary supplements for human beings, Bacteriological preparations, other than for medical and veterinary use, Bacteriological cultures for adding to food, milk and dairy products, including fermented milk products, Not for medical or veterinary purposes, Cultures of microorganisms other than for medical use, cultures of microorganisms for use in making food and beverages, preparations based on microorganisms, Not for medical or veterinary purposes, bacterial substances for industrial use, Bacteria for use in food manufacture, Chemical preparations for use in cosmetic products, Bacterial preparations for the food industry, Bacterial cultures for addition to food products, Bacterial preparations and cultures not for medical use, Milk ferments and bacterial preparations for use in producing foodstuffs, Antioxidants, fatty acids, proteins, enzymes, liposomes, cultures of microorganisms, bacteria for producing lactic acid and probiotic compositions, all for use in producing the following goods: pharmaceuticals, Dietetic compounds for humans, Baby food, Nutritional supplements, Nutritional supplements, dietary supplements, Dietary supplements for medical purposes and dietetic food, probiotic bacteria for the food industry, Probiotic bacterial preparations (not for medical use), fermentation extracts for industrial purposes; Wholesaling and retailing for others including via mail order and via communications media including the internet, in relation the following goods: pharmaceuticals, Medical and veterinary preparations containing live and/or dead microorganisms, Sanitary preparations for medical purposes, Preparations of microorganisms for medical and veterinary purposes, Bacteriological preparations for medical and veterinary use, Pharmaceuticals and pharmaceutical preparations, including the following goods: pharmaceuticals, Parapharmaceuticals, Milk ferments, Probiotic ferments, Probiotics, Nutraceuticals, nutritional, Medical preparations for food, nutritional, dietetic, vitamin, nutraceutical, probiotic, prebiotic and pharmaceutical use, pharmaceuticals and food supplements, Bacteriological cultures for adding to milk, dairy products and fermented milk products, for medical use, food additives based on milk and dairy products, including fermented milk products, for use as dietary supplement (not for medical use), vitamins, Dietary fiber to aid digestion, Dietary fibre for use as an ingredient in the production of dietary supplements, Vitamin-fortified beverages, Dietetic beverages adapted for medical, Dietetic food and substances adapted for medical use, dietetic food and substances for babies for medical use, functional and nutraceutical food, not for medical use, dietary supplements for medical use and dietary supplements for human beings featuring at least one of the following compounds: trace elements, mineral salts, Metal oxides, Metal hydroxides, Phosphoric acid salts, vitamins, Proteins, antioxidants, enzymes, liposomes, hyaluronic acid, milk protein, Microelements, Organic acid salts, Inorganic acids and salts thereof, saturated or unsaturated fatty acids, oils, fats and lipids of plant and/or animal origin, amino acids, Glucose, Starch, rice starch, Carbohydrates, Saccharic esters in fatty acids, Lecithin and Sunflower lecithin, omega 3 and omega-6, Probiotic bacterial preparations for medical purposes and for animals.

84.

Methods for the treatment of psoriatic arthritis

      
Application Number 17057946
Grant Number 12329758
Status In Force
Filing Date 2019-05-23
First Publication Date 2021-09-30
Grant Date 2025-06-17
Owner ALFASIGMA S.P.A. (Italy)
Inventor
  • Harrison, Pille
  • Meuleners, Luc
  • Tasset, Chantal Thérèse

Abstract

The present invention relates to compound according to Formula I: or a pharmaceutically acceptable salt thereof, or a solvate or the salt of a solvate thereof, pharmaceutical compositions comprising the same, and methods of treatment using the same, for use in the treatment of psoriatic arthritis, by administering the compound according to Formula I.

IPC Classes  ?

  • A61K 31/541 - Non-condensed thiazines containing further heterocyclic rings
  • A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis

85.

Farnesoid X receptor modulators

      
Application Number 17320286
Grant Number 12291549
Status In Force
Filing Date 2021-05-14
First Publication Date 2021-09-02
Grant Date 2025-05-06
Owner ALFASIGMA S.P.A (Italy)
Inventor
  • Pellicciari, Roberto
  • Gioiello, Antimo

Abstract

The present application provides a compound of formula I: are as described herein. The present invention relates generally to FXR modulators and to methods of making and using said compounds.

IPC Classes  ?

  • C07J 31/00 - Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
  • C07J 9/00 - Normal steroids containing carbon, hydrogen, halogen, or oxygen, substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
  • C07J 41/00 - Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
  • C07J 43/00 - Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta[a]hydrophenanthrene skeleton
  • C07J 71/00 - Steroids in which the cyclopenta[a]hydrophenanthrene skeleton is condensed with a heterocyclic ring

86.

Salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders

      
Application Number 17144788
Grant Number 11667633
Status In Force
Filing Date 2021-01-08
First Publication Date 2021-09-02
Grant Date 2023-06-06
Owner ALFASIGMA S.P.A. (Italy)
Inventor
  • Sabourault, Nicolas Luc
  • Wigerinck, Piet

Abstract

The present invention discloses salts of a Compound 1: useful in the prophylaxis and/or treatment of inflammatory conditions, autoimmune diseases, proliferative diseases, allergy, transplant rejection, diseases involving degradation and/or disruption of cartilage homeostasis, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6 or interferons.

IPC Classes  ?

  • C07D 471/04 - Ortho-condensed systems
  • H04W 4/80 - Services using short range communication, e.g. near-field communication [NFC], radio-frequency identification [RFID] or low energy communication
  • H04L 9/40 - Network security protocols
  • H04L 67/104 - Peer-to-peer [P2P] networks
  • H04W 8/24 - Transfer of terminal data
  • H04L 67/51 - Discovery or management thereof, e.g. service location protocol [SLP] or web services
  • A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
  • A61K 31/541 - Non-condensed thiazines containing further heterocyclic rings
  • A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
  • H04W 92/18 - Interfaces between hierarchically similar devices between terminal devices

87.

Probiotics for use in the treatment of diverticulosis and diverticular disease

      
Application Number 16467797
Grant Number 11896631
Status In Force
Filing Date 2017-12-15
First Publication Date 2021-08-05
Grant Date 2024-02-13
Owner ALFASIGMA S.P.A. (Italy)
Inventor
  • Biffi, Andrea
  • Fiore, Walter
  • Rossi, Ruggero

Abstract

The present invention relates to the use of probiotics to control the inflammatory process of the colon in subjects with structural modifications of the colon wall, preferably in subjects with diverticulosis, and affected by diverticular disease.

IPC Classes  ?

  • A01N 63/00 - Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates
  • A61K 35/747 - Lactobacilli, e.g. L. acidophilus or L. brevis
  • A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics
  • A61K 9/00 - Medicinal preparations characterised by special physical form
  • A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
  • A61K 35/745 - Bifidobacteria
  • A61K 36/06 - Fungi, e.g. yeasts

88.

DYFESA

      
Application Number 1603844
Status Registered
Filing Date 2021-05-03
Registration Date 2021-05-03
Owner ALFASIGMA S.P.A. (Italy)
NICE Classes  ?
  • 05 - Pharmaceutical, veterinary and sanitary products
  • 10 - Medical apparatus and instruments

Goods & Services

Pharmaceuticals, medical and veterinary preparations; sanitary preparations for medical purposes; dietetic food and substances adapted for medical or veterinary use, food for babies; dietary supplements for human beings and animals; plasters, materials for dressings; dietetic food and substances for babies; dietetic food and substances for babies adapted for medical use; food supplements: dietary supplements; nutraceuticals for use as dietary supplements; functional foodstuffs and nutraceuticals for medical purposes; nutritional additives for medical use; foods for special medical purposes; medical preparations, in particular medical devices pursuant to regulation EU2017/745; drug delivery agents; delivery agents for dietary supplements; active ingredients and pharmaceutical and veterinary active substances; pharmaceutical preparations for inhalers; medicinal sprays; inhalants. Surgical, medical, and veterinary apparatus and instruments; therapeutic and assistive devices adapted for persons with disabilities; apparatus, devices and articles for nursing infants; inhalers for medical use; spray bottles [vaporizers] for medical use; cans [spray] for medical use; aerosol dispenser for medical purposes; pipetting instruments for medical use; apparatus for administering drugs by inhalation.

89.

Compositions comprising bacterial strains for use in increasing the bioavailability of amino acids derived from proteins, and related food product methods and systems

      
Application Number 17090669
Grant Number 11751597
Status In Force
Filing Date 2020-11-05
First Publication Date 2021-06-24
Grant Date 2023-09-12
Owner ALFASIGMA S.P.A. (Italy)
Inventor
  • Biffi, Andrea
  • Fiore, Walter

Abstract

Lactobacillus paracasei LPC-S01™ DSM 26760, and possibly. The compositions food products, methods and systems o the disclosure, can further comprise at least one protein, preferably proteins of plant origin, or a peptide or an amino acid, and in particular includes a food product comprising proteins, preferably of plant origin, and said mixture M of at least one bacterial strain.

IPC Classes  ?

  • C12N 1/20 - BacteriaCulture media therefor
  • A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics
  • A61K 35/747 - Lactobacilli, e.g. L. acidophilus or L. brevis

90.

LP-DG

      
Application Number 018482606
Status Registered
Filing Date 2021-05-31
Registration Date 2021-10-12
Owner ALFASIGMA S.p.A. (Italy)
NICE Classes  ?
  • 01 - Chemical and biological materials for industrial, scientific and agricultural use
  • 03 - Cosmetics and toiletries; cleaning, bleaching, polishing and abrasive preparations
  • 05 - Pharmaceutical, veterinary and sanitary products
  • 35 - Advertising and business services

Goods & Services

Raw materials [chemical], chemicals, chemical additives and compositions for use in industry for the formulation and preparation of the following goods: Pharmaceuticals, Parapharmaceutical preparations, nutraceutical preparations, Nutritional products, Dietetic food and substances, dietetic food and substances adapted for medical use, Dietetic food and substances for babies, adapted for medical use, Functional foodstuffs and nutraceuticals for medical purposes, Food-supplements for medical use, Dietary supplements for human beings; Bacteriological preparations, other than for medical and veterinary use; Bacteriological cultures for adding to food, milk and dairy products, including fermented milk products, other than for medical and veterinary use; Cultures of microorganisms other than for medical use; Cultures of microorganisms for use in making food and beverages; Preparations of microorganisms, other than for medical and veterinary use; Bacterial substances for industrial use; Bacteria for use in food manufacture; Chemical preparations for use in the manufacture of cosmetics; Bacterial preparations for the food industry; Bacterial cultures for addition to food products; Bacterial preparations and cultures other than for medical use; Milk ferments and bacterial preparations for use in producing foodstuffs; Antioxidants, fatty acids, proteins, enzymes, liposomes, cultures of microorganisms, bacteria for producing lactic acid and probiotic compositions, all for use in producing the following goods: Pharmaceuticals, Dietetic compounds for humans, Food for babies, Food supplements, Nutritional supplements, Dietetic supplements, Food-supplements for medical use and Dietetic food; Probiotic bacteria for the food industry; Preparations of probiotic bacteria, other than for medical; Fermentation extracts for industrial purposes; Probiotic bacterial preparations for medical purposes and for animals. Cosmetics featuring live or dead microorganisms; Cosmetics and cosmetic preparations based on microorganisms, lactic bacteria and/or bifidobacteria; Functional cosmetics based on microorganisms, lactic bacteria and/or bifidobacteria; Non-medicated cosmetics; Cosmetics containing hyaluronic acid, Cosmetics featuring microorganisms. Preparations of microorganisms for medical or veterinary use; Bacteriological preparations for medical and veterinary purposes; Pharmaceuticals and pharmaceutical preparations, including the following goods: Pharmaceuticals, Parapharmaceutical preparations, Milk ferments, Probiotic ferments, Probiotics, Nutraceuticals, Nutritional preparations; Medical preparations for food, nutritional, dietetic, vitamin, nutraceutical, probiotic, prebiotic and pharmaceutical use; Pharmaceutical preparations and dietary supplements; Bacteriological cultures for adding to milk, dairy products and fermented milk, for medical use; Lactic bacteria, For medical purposes; Food additives based on milk and dairy products, including fermented milk products, for use as dietary supplement (not for medical use); Vitamins; Dietary fiber to aid digestion; Dietary fibre for use as ingredients in the production of dietary supplements, vitamin drinks, dietetic beverages adapted for medical use; Dietetic food and substances adapted for medical use, dietetic food and substances for babies for medical use, functional and nutraceutical food, not for medical use, dietary supplements for medical use and dietary supplements for human beings featuring at least one of the following compounds: Trace elements, Mineral salts, Metal oxides, Metal hydroxides, Salts of phosphoric acid, Vitamins, Protein, Milk proteins, Microelements, Organic acids and their salts, Inorganic acids and their salts, Saturated and unsaturated fatty acids, Oils, fats and lipids of plant and/or animal origin, Amino acid, Glucose, Stiffeners, Rice starch, Carbohydrates, Saccharic esters in fatty acids, Lecithin and sunflower lecithin, Omega 3 and Omega-6. Wholesaling and retailing for others including via mail order and via communications media including the internet, in relation the following goods: Raw materials [chemical], chemicals, chemical additives and compositions for use in industry for the formulation and preparation of the following goods: pharmaceuticals, Health and beauty goods, Nutraceutical preparations, nutritional products, dietetic food and substances, Dietetic foodstuffs and substances adapted for medical use, Dietetic food and substances for babies adapted for medical use, Functional foodstuffs and nutraceuticals for medical purposes, Nutritional additives for medical purposes, Dietary supplements for human beings, Medical preparations for food, nutritional, dietetic, vitamin, nutraceutical, probiotic, prebiotic and pharmaceutical use, pharmaceuticals and food supplements, Bacteriological preparations, other than for medical and veterinary use, Bacteriological cultures for adding to food, milk and dairy products, including fermented milk products, Not for medical or veterinary purposes, Cultures of microorganisms other than for medical use, cultures of microorganisms for use in making food and beverages, preparations based on microorganisms, Not for medical or veterinary purposes, bacterial substances for industrial use, Bacteria for use in food manufacture, Chemical preparations for use in cosmetic products, Bacterial preparations for the food industry, Bacterial cultures for addition to food products, Bacterial preparations and cultures not for medical use, Milk ferments and bacterial preparations for use in producing foodstuffs, Antioxidants, fatty acids, proteins, enzymes, liposomes, cultures of microorganisms, bacteria for producing lactic acid and probiotic compositions, all for use in producing the following goods: pharmaceuticals, Dietetic compounds for humans, Baby food, Nutritional supplements, Nutritional supplements, dietary supplements, Dietary supplements for medical purposes and dietetic food, probiotic bacteria for the food industry, Probiotic bacterial preparations (not for medical use), fermentation extracts for industrial purposes, Probiotic bacterial preparations for medical purposes and for animals; Wholesaling and retailing for others including via mail order and via communications media including the internet, in relation the following goods: Cosmetics featuring live or dead microorganisms, cosmetics and cosmetic preparations based on microorganisms, lactic bacteria and/or bifidobacteria, functional cosmetics based on microorganisms, lactic bacteria and/or bifidobacteria, non-medicated cosmetics, Cosmetics featuring hyaluronic acid and microorganisms; Wholesaling and retailing for others including via mail order and via communications media including the internet, in relation the following goods: Preparations of microorganisms for medical and veterinary purposes, Bacteriological preparations for medical and veterinary use, Pharmaceutical products and preparations, namely pharmaceutical preparations, parapharmaceuticals, milk ferments, probiotic ferments, probiotics, nutraceuticals, nutritional products, pharmaceuticals and food supplements, Bacteriological cultures for adding to milk, dairy products and fermented milk products, for medical use, food additives based on milk and dairy products, including fermented milk products, for use as dietary supplement (not for medical use), vitamins, Dietary fiber to aid digestion, Dietary fibre for use as an ingredient in the production of dietary supplements, Vitamin-fortified beverages, Dietetic beverages adapted for medical, Dietetic food and substances adapted for medical use, dietetic food and substances for babies for medical use, functional and nutraceutical food, not for medical use, dietary supplements for medical use and dietary supplements for human beings featuring at least one of the following compounds: trace elements, mineral salts, Metal oxides, Metal hydroxides, Phosphoric acid salts, vitamins, Proteins, milk protein, Microelements, organic acids and salts thereof, inorganic acids and salts thereof, saturated or unsaturated fatty acids, oils, fats and lipids of plant and/or animal origin, amino acids, Glucose, Starch, rice starch, Carbohydrates, Saccharic esters in fatty acids, Lecithin and Sunflower lecithin, omega 3 and omega-6.

91.

DG

      
Serial Number 79324218
Status Registered
Filing Date 2021-05-31
Registration Date 2022-09-27
Owner ALFASIGMA S.P.A. (Italy)
NICE Classes  ?
  • 01 - Chemical and biological materials for industrial, scientific and agricultural use
  • 05 - Pharmaceutical, veterinary and sanitary products
  • 35 - Advertising and business services

Goods & Services

Raw materials being chemical, chemicals, additives and chemical compounds intended for industry for use in the manufacture of pharmaceutical, parapharmaceutical, nutraceutical, nutritional, food and dietary substances, food and dietary substances for medical use, dietary food and substances for babies for medical use, functional and nutraceutical food for medical use, food supplements for medical use, food supplements for humans, pharmaceutical products and food supplements; bacteriological preparations other than those for medical and veterinary use; bacteriological cultures to be added to foods, milk and dairy products, including fermented milk products, other than for medical and veterinary use; cultures of microorganisms not for medical or veterinary purposes; cultures of microorganisms for use in the manufacture of food and beverages, other than for medical or veterinary use; preparations being cultures of microorganisms, not for medical or veterinary use; bacterial preparation substances for industrial use, other than for medical or veterinary use; bacterial preparations used in food production, other than for medical or veterinary use; perfluorinated chemical compounds prepared synthetically for use in the manufacture of cosmetics; bacterial preparations for the food industry, other than for medical or veterinary use; additive bacterial cultures for food products, other than for medical or veterinary use; bacterial preparations and cultures not for medical use and addition to food products; lactic fermentation extracts and bacterial preparations used for production of foods, other than for medical or veterinary use; chemicals and chemical preparations, namely, antioxidants, fatty acids, proteins, enzymes, liposomes, cultures of microorganisms, bacteria to produce lactic acid and probiotic compounds, all intended for the manufacture of pharmaceuticals, dietary compounds for human use, baby food, food supplements, nutritional supplements, dietary supplements, food supplements for medical use and dietary foods; probiotic bacteria for use in the manufacture of food supplements; preparations of probiotic bacteria not for medical use, for use in the manufacture of food supplements; fermentation extracts for industrial use Preparations of microorganisms for medical or veterinary use; bacteriological preparations for medical and veterinary use; pharmaceutical products and preparations, namely, pharmaceutical products for the treatment of indigestion, parapharmaceutical for the treatment of indigestion, lactic ferments for pharmaceutical purposes, probiotic ferments for pharmaceutical purposes, probiotic supplements, nutraceuticals for use as a dietary supplement, nutritional supplements; pharmaceutical products for the treatment of infectious diseases; food supplements; bacteriological culture preparations to add to milk, dairy products and fermented milk for medical purposes; lactic bacterial preparations for medical purposes; dietary supplements being comprised of milk and dairy products, including fermented milk products; vitamins; dietary fibers to aid digestion; dietary fibers for use as an ingredient in the manufacture of dietary supplements, vitamin supplement drinks, dietary supplement drinks for medical use; dietary and nutritional supplements, namely, food and dietetic substances for medical use, food and dietetic substances for infants for medical use, functional foods and nutraceuticals for medical use, food supplements for medical use and food supplements for humans comprising at least one selected compound trace elements, mineral salts, oxides of metals, metal hydroxides, phosphoric acid salts, vitamins, proteins, milk proteins, microelements, organic acids and their salts, inorganic acids and their salts, saturated or unsaturated fatty acids, oils, fats and lipids of vegetable origin and animal, amino acids, glucose, starch, rice starch, carbohydrates, saccharic esters of fatty acids, sunflower lecithin and lecithin, omega-3 and omega-6; probiotic bacterial preparations for medical and veterinary use Wholesale and retail store services for the benefit of third parties including by mail order and through the means of communication including the internet, in relation to raw materials in the nature of chemical, chemicals, additives and chemical compounds intended for industry for formulation and preparation of pharmaceutical, parapharmaceutical, nutraceutical, nutritional, food and dietary substances, food and dietary substances for medical use, dietary food and substances for babies for medical use, functional and nutraceutical food for medical use, food supplements for medical use, food supplements for humans, medical preparations, namely, medical devices, pharmaceutical products and food supplements, bacteriological preparations other than those for medical and veterinary use, bacteriological cultures to be added to foods, milk and dairy products, including fermented milk products, other than for medical and veterinary use, cultures of microorganisms not for medical purposes, cultures of microorganisms for use in the manufacture of food and beverages, preparations based on microorganisms, not for medical or veterinary use, bacterial substances for industrial use, bacteria used in food production, chemical preparations for cosmetics, bacterial preparations for the food industry, additive bacterial cultures for food products, bacterial preparations and cultures not for medical use, lactic ferments and bacterial preparations used for production of foods, antioxidants, fatty acids, proteins, enzymes, liposomes, cultures of microorganisms, bacteria to produce lactic acid and probiotic compounds all intended for the production of pharmaceuticals, dietary compounds for human use, baby food, food supplements, nutritional supplements, dietary supplements, food supplements for medical use and dietary foods, probiotic bacteria for the food industry, preparations of probiotic bacteria not for medical use, fermentation extracts for industrial use, probiotic bacterial preparations for medical and animal use; wholesale and retail store services for the benefit of third parties including by mail order and through the means of communication including the internet, in relation to preparations of microorganisms for medical or veterinary use, bacteriological preparations for medical and veterinary use, pharmaceutical products and preparations, including pharmaceutical products, parapharmaceuticals, lactic ferments, probiotic ferments, probiotics, nutraceuticals, nutritional, medical preparations, namely, medical devices, pharmaceutical products and food supplements, bacteriological cultures to add to milk, dairy products and fermented milk for medical purposes, lactic bacteria for medical purposes, food additives based on milk and dairy products, including fermented milk products, for use as a dietary supplement not for medical purposes, vitamins, dietary fibers to aid digestion, dietary fibers for use as an ingredient in the manufacture of dietary supplements, vitamin drinks, dietary drinks for medical use, food and dietetic substances for medical use, food and dietetic substances for infants for medical use, functional foods and nutraceuticals for medical use, food supplements for medical use and food supplements for humans comprising at least one selected compound trace elements, mineral salts, oxides of metals, metal hydroxides, phosphoric acid salts, vitamins, proteins, milk proteins, microelements, organic acids and their salts, inorganic acids and their salts, saturated or unsaturated fatty acids, oils, fats and lipids of vegetable origin and animal, amino acids, glucose, starch, rice starch, carbohydrates, saccharic esters of fatty acids, sunflower lecithin and lecithin, omega-3 and omega-6

92.

DG

      
Application Number 214315900
Status Registered
Filing Date 2021-05-31
Registration Date 2024-05-17
Owner ALFASIGMA S.P.A. (Italy)
NICE Classes  ?
  • 01 - Chemical and biological materials for industrial, scientific and agricultural use
  • 05 - Pharmaceutical, veterinary and sanitary products
  • 35 - Advertising and business services

Goods & Services

(1) Active chemical ingredients for use in the manufacture of food, of medicine, of pharmaceuticals, parapharmaceuticals, nutraceuticals; chemical additives for use in the manufacture of food, of medicine, of pharmaceuticals, parapharmaceuticals, nutraceuticals; chemical compositions for use in the manufacture of food, of medicine, of pharmaceuticals, parapharmaceuticals, nutraceuticals; chemical compounds for use in the manufacture of food, of medicine, of pharmaceuticals, parapharmaceuticals, nutraceuticals, in accordance with EU regulation 2017/745; bacteriological preparations for the food industry; bacteriological cultures to be added to foods, milk and dairy products, including fermented milk products, other than for medical and veterinary use; cultures of bacterial microorganisms for laboratory and scientific research; cultures of microorganisms for use in the manufacture of food and beverages; bacteria used in food production; chemical preparations for use in the manufacture of cosmetics; bacterial preparations for the food industry; additive bacterial cultures for food products; bacterial preparations and cultures for the food industry; lactic ferments and bacterial preparations used for production of foods; antioxidants, fatty acids, proteins, enzymes, liposomes, cultures of microorganisms, bacteria to produce lactic acid and probiotic compounds all intended for the production of pharmaceuticals, dietary compounds for human use, baby food, food supplements, nutritional supplements, dietary supplements, food supplements for medical use and dietary foods; probiotic bacteria for the food industry; preparations of probiotic bacteria for the food industry; fermentation extracts for industrial use, namely biological microorganisms used in the manufacture of pharmaceuticals. (2) Dietary supplements containing microorganisms for gastrointestinal health; probiotic bacterial formulations for medical and veterinary use; pharmaceutical products and preparations, namely pharmaceutical products, parapharmaceuticals, lactic ferments, probiotic ferments, probiotics, nutraceuticals, and nutritional supplements for gastrointestinal health; pharmaceutical products and food supplements for gastrointestinal health, in accordance with EU regulation 2017/745; bacteriological cultures to add to milk, dairy products and fermented milk for medical purposes; lactic bacteria for medical purposes; food additives based on milk and dairy products, including fermented milk products, for use as a dietary supplement (not for medical purposes); vitamins; dietary fibers to aid digestion; dietary fibers for use as an ingredient in the manufacture of dietary supplements, vitamin drinks, dietary drinks for medical use; food preparations for babies and infants; mineral food supplements, namely food supplements containing at least one selected compound trace elements of mineral salts, oxides of metals, metal hydroxides, phosphoric acid salts, vitamins, proteins, milk proteins, microelements, organic acids and their salts, inorganic acids and their salts, saturated and unsaturated fatty acids, oils, fats and lipids of vegetable origin and animal, amino acids, glucose, starch, rice starch, carbohydrates, saccharic esters of fatty acids, sunflower lecithin and lecithin, omega-3 and omega-6; probiotic bacterial preparations for medical and animal use. (1) Wholesale and retail services for the benefit of third parties including by mail order and through the means of communication including the internet, in relation to raw materials [chemical], chemicals, additives and chemical compounds intended for industry for formulation and preparation of pharmaceutical, parapharmaceutical, nutraceutical, nutritional, food and dietary substances, food and dietary substances for medical use, dietary food and substances for babies for medical use, functional and nutraceutical food for medical use, food supplements for medical use, food supplements for humans, medical preparations, namely medical devices pursuant to EU regulation 2017/745, pharmaceutical products and food supplements, in accordance with EU regulation 2017/745, bacteriological preparations other than those for medical and veterinary use, bacteriological cultures to be added to foods, milk and dairy products, including fermented milk products, other than for medical and veterinary use, cultures of microorganisms not for medical purposes, cultures of microorganisms for use in the manufacture of food and beverages, preparations based on microorganisms, not for medical or veterinary use, bacterial substances for industrial use, bacteria used in food production, chemical preparations for cosmetics, bacterial preparations for the food industry, additive bacterial cultures for food products, bacterial preparations and cultures not for medical use, lactic ferments and bacterial preparations used for production of foods, antioxidants, fatty acids, proteins, enzymes, liposomes, cultures of microorganisms, bacteria to produce lactic acid and probiotic compounds all intended for the production of pharmaceuticals, dietary compounds for human use, baby food, food supplements, nutritional supplements, dietary supplements, food supplements for medical use and dietary foods, probiotic bacteria for the food industry, preparations of probiotic bacteria [not for medical use], fermentation extracts for industrial use, probiotic bacterial preparations for medical and animal use; wholesale and retail services for the benefit of third parties including by mail order and through the means of communication including the internet, in relation to preparations of microorganisms for medical or veterinary use, bacteriological preparations for medical and veterinary use, pharmaceutical products and preparations, including pharmaceutical products, parapharmaceuticals, lactic ferments, probiotic ferments, probiotics, nutraceuticals, nutritional, medical preparations, namely medical devices pursuant to EU regulation 2017/745, pharmaceutical products and food supplements, in accordance with EU regulation 2017/745, bacteriological cultures to add to milk, dairy products and fermented milk for medical purposes, lactic bacteria for medical purposes, food additives based on milk and dairy products, including fermented milk products, for use as a dietary supplement (not for medical purposes), vitamins, dietary fibers to aid digestion, dietary fibers for use as an ingredient in the manufacture of dietary supplements, vitamin drinks, dietary drinks for medical use, food and dietetic substances for medical use, food and dietetic substances for infants for medical use, functional foods and nutraceuticals for medical use, food supplements for medical use and food supplements for humans comprising at least one selected compound trace elements, mineral salts, oxides of metals, metal hydroxides, phosphoric acid salts, vitamins, proteins, milk proteins, microelements, organic acids and their salts, inorganic acids and their salts, saturated or unsaturated fatty acids, oils, fats and lipids of vegetable origin and animal, amino acids, glucose, starch, rice starch, carbohydrates, saccharic esters of fatty acids, sunflower lecithin and lecithin, omega-3 and omega-6.

93.

DYFESA

      
Serial Number 79316891
Status Registered
Filing Date 2021-05-03
Registration Date 2022-09-27
Owner ALFASIGMA S.P.A. (Italy)
NICE Classes  ?
  • 05 - Pharmaceutical, veterinary and sanitary products
  • 10 - Medical apparatus and instruments

Goods & Services

Pharmaceuticals, medical and veterinary preparations, namely, pain relief medication and antibiotics; sanitary preparations for medical purposes; dietetic food and beverages adapted for medical or veterinary use, food for babies; dietary supplements for human beings and animals; medical plasters, medical dressings; dietetic food and beverages for babies; dietetic food and beverages for babies adapted for medical use; food supplements; dietary supplements; nutraceuticals for use as dietary supplements; medicated supplements for foodstuffs for babies and animals; Nutraceuticals for use as a dietary supplement for medical purposes; nutritional food additives for medical use in the nature of natural food extracts derived from fish, meat, and vegetables; dietetic foods adapted for special medical use; medical preparations, namely, nutritional supplements; drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; delivery agents in the form of tablets for the delivery of dietary supplements; drug delivery agents in the form of powders that provide controlled release of the active ingredients for a wide variety of pharmaceuticals and veterinary active substances; pharmaceutical preparations for inhalers for the treatment of respiratory diseases and disorders; medicinal preparations for the mouth and as sprays; inhalant anesthetics Surgical apparatus and instruments for medical, dental or veterinary use; therapeutic and assistive devices adapted for persons with disabilities, namely, medical and therapeutic device and apparatus, namely, a force and motion sensing apparatus and assisted exercise machine for the rehabilitation of hands and wrists, feet and ankles, knees affected by neuromuscular diseases, disorders, or injuries for home or clinical use; apparatus, devices and articles for nursing infants, namely, nursing bottles; inhalers for medical use; spray bottles being vaporizers for medical use; spray cans in the nature of aerosol dispenser for medical use; aerosol dispenser for medical purposes; dropping pipetting instruments for medical use; apparatus for administering drugs by inhalation, namely, inhalers for medical use

94.

Can we simplify the journey in UC?

      
Application Number 018441402
Status Registered
Filing Date 2021-03-30
Registration Date 2021-08-04
Owner ALFASIGMA S.p.A. (Italy)
NICE Classes  ?
  • 35 - Advertising and business services
  • 36 - Financial, insurance and real estate services
  • 44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services

Goods & Services

Promoting public awareness of treatment guidelines; promoting public awareness of inflammatory and autoimmune diseases; Administratively assisting patients in enrolling in pharmaceutical reimbursement and benefit programs. Financially assisting patients, pharmacists, and healthcare providers with respect to reimbursement of medicines. Information and advisory services relating to pharmaceuticals, diseases and medical conditions and treatment, including such services provided on-line from a computer network or the Internet; providing information and advisory services regarding the diagnosis and treatment of diseases and medical disorders.

95.

EURARTESIM

      
Serial Number 90543804
Status Registered
Filing Date 2021-02-24
Registration Date 2022-04-19
Owner ALFASIGMA S.P.A. (Italy)
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

Antimalarial pharmaceutical preparations for oral or injectable use

96.

POLMONYDEFENCE

      
Application Number 1572409
Status Registered
Filing Date 2020-10-01
Registration Date 2020-10-01
Owner ALFASIGMA S.P.A. (Italy)
NICE Classes  ?
  • 05 - Pharmaceutical, veterinary and sanitary products
  • 10 - Medical apparatus and instruments

Goods & Services

Pharmaceuticals, medical and veterinary preparations; sanitary preparations for medical purposes; dietetic food and substances adapted for medical or veterinary use, food for babies; dietary supplements for human beings and animals; plasters, materials for dressings, dietetic food and substances for babies; dietetic food and substances for babies adapted for medical use; food supplements; dietary supplements; nutraceuticals for use as dietary supplements; functional foodstuffs and nutraceuticals for medical purposes; nutritional additives for medical use; foods for special medical purposes; medical preparations, in particular pharmaceuticals pursuant to regulation EU 2017/745; drug delivery agents; delivery agents for dietary supplements; pharmaceutical and veterinary substances; pharmaceutical preparations for inhalers; medicinal sprays; inhalants. Surgical, medical, dental and veterinary apparatus and instruments; therapeutic and assistive devices adapted for persons with disabilities; apparatus, devices and articles for nursing infants, inhalers for medical use; spray bottles [vaporizers] for medical use; cans [spray] for medical use; aerosol dispenser for medical purposes; pipetting instruments for medical use; apparatus for administering drugs by inhalation.

97.

POLMONYAIR

      
Application Number 1567241
Status Registered
Filing Date 2020-10-01
Registration Date 2020-10-01
Owner ALFASIGMA S.P.A. (Italy)
NICE Classes  ?
  • 05 - Pharmaceutical, veterinary and sanitary products
  • 10 - Medical apparatus and instruments

Goods & Services

Pharmaceuticals, medical and veterinary preparations; sanitary preparations for medical purposes; dietetic food and substances adapted for medical or veterinary use, food for babies; dietary supplements for human beings and animals; plasters, materials for dressings; dietetic food and substances for babies; dietetic food and substances for babies adapted for medical use; food supplements; dietary supplements; nutraceuticals for use as dietary supplements; functional foodstuffs and nutraceuticals for medical purposes; nutritional additives for medical use; foods for special medical purposes; medical preparations, in particular medical devices pursuant to regulation EU 2017/745; drug delivery agents; delivery agents for dietary supplements; active ingredients and pharmaceutical and veterinary active substances; pharmaceutical preparations for inhalers; medicinal sprays; inhalants. Surgical, medical, dental and veterinary apparatus and instruments; therapeutic and assistive devices adapted for persons with disabilities; apparatus, devices and articles for nursing infants; inhalers for medical use; spray bottles [vaporizers] for medical use; cans [spray] for medical use; aerosol dispenser for medical purposes; pipetting instruments for medical use; apparatus for administering drugs by inhalation.

98.

PHARMACEUTICAL COMPOSITIONS IN THE FORM OF GEL CONTAINING XYLOGLUCAN AND ALCOHOLS FOR THE CONTROLLED RELEASE OF ACTIVE INGREDIENTS

      
Application Number EP2020066181
Publication Number 2020/254179
Status In Force
Filing Date 2020-06-11
Publication Date 2020-12-24
Owner ALFASIGMA S.P.A. (Italy)
Inventor
  • Viscomi, Giuseppe, Claudio
  • Maffei, Paola
  • Bruno, Cristiana
  • Federici, Mascia
  • Dispenza, Clelia
  • Sabatino, Maria, Antonietta

Abstract

The invention relates to gel compositions comprising pharmaceutical active ingredients. The composition comprises xyloglucan at a concentration between 0.1% and 10.0% by total weight of the composition, together with a primary alcohol at a concentration between 20.0 and 50.0% by total weight of the composition. The invention also describes a process for the preparation of the composition and its use in the treatment of pathologies wherein a controlled release of the active principle is useful.

IPC Classes  ?

  • A61K 9/06 - OintmentsBases therefor
  • A61K 38/21 - Interferons
  • A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
  • A61K 47/36 - PolysaccharidesDerivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
  • A61K 9/00 - Medicinal preparations characterised by special physical form

99.

ALFAGERD

      
Application Number 1558720
Status Registered
Filing Date 2020-08-21
Registration Date 2020-08-21
Owner ALFASIGMA S.P.A. (Italy)
NICE Classes  ?
  • 05 - Pharmaceutical, veterinary and sanitary products
  • 10 - Medical apparatus and instruments

Goods & Services

Pharmaceutical preparations for treating digestive system disorders; pharmaceutical preparations and substances for the treatment of gastrointestinal diseases; medicines for the treatment of gastrointestinal diseases; pharmaceutical preparations and substances for the treatment of gastroesophageal reflux; pharmaceutical preparations and substances for the protection of the esophagus in case of gastroesophageal reflux; pharmaceutical preparations for the treatment of digestive diseases. Medical devices for the treatment of gastrointestinal diseases; medical devices for treating gastroesophageal reflux; medical devices for the protection of the esophagus in case of gastroesophageal reflux.

100.

MYMENTUM

      
Application Number 018328885
Status Registered
Filing Date 2020-11-02
Registration Date 2021-03-20
Owner ALFASIGMA S.p.A. (Italy)
NICE Classes  ?
  • 35 - Advertising and business services
  • 36 - Financial, insurance and real estate services
  • 44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services

Goods & Services

Promoting public awareness of treatment guidelines; promoting public awareness of inflammatory and autoimmune diseases; assisting patients in enrolling in pharmaceutical reimbursement and benefit programs. Assisting patients, pharmacists, and healthcare providers with respect to reimbursement of medicines. Information and advisory services relating to pharmaceuticals, diseases and medical conditions and treatment, including such services provided on-line from a computer network or the Internet; providing information and advisory services regarding the diagnosis and treatment of diseases and medical disorders.
  1     2     3     ...     6        Next Page